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ABSTRACT 
Being a very heterogeneous disease, rheumatoid arthritis (RA) is challenging for treatment. 
On a group level, some therapy options might be superior compared with others, however, 
this does not mutually exclude the less effective option to be more suitable for some patients, 
if the superior therapy option does not help. In different patients the concentration of 
biomarkers may vary dramatically, however, translation of meaning of these variations for 
each patient is not feasible yet. Observations and comparisons of these biomarkers before start 
of therapy between patient groups with different outcome after therapy can help to understand 
their role and make individualised approach for the therapy choice. 
Low or moderate levels of a multi-biomarker disease activity (MBDA) score measured at 
baseline or follow-up visits could identify RA patients at very low risk of radiographic 
progression (RP). Moreover, in patients with high MBDA score at the start of treatment 
escalation, those on infliximab+methotrexate (IFX+MTX) therapy had significantly less RP 
than patients on non-biological triple therapy (TT) (papers I and II). 
In treatment-naive, early RA, patients who failed respond to MTX were randomized to 
IFX+MTX or non-biological TT. The categories of the MBDA score at the time of 
randomisation were differentially associated with treatment outcome after 1 year for these two 
therapies. Patients with low MBDA score benefited more from TT, while those with high 
MBDA score responded better to IFX (paper III). 
Furthermore, when the 12 component biomarkers of the MBDA score were analysed at 
baseline, four of those (paper IV) as well as two of 177 proteins retrieved from an affinity 
proteomic study (paper V) were associated with treatment outcome: low disease activity 
(LDA) and EULAR good response after 3 months of MTX therapy. Combination of these 
biomarkers within each study also showed improved prediction of treatment outcome. 
In patients failing on MTX monotherapy who were randomised to addition of biological TNF 
inhibitor IFX, very low serum IFX (sIFX) level and anti-drug antibody (ADA)-positivity were 
associated with poorer outcome. Among baseline parameters, female gender predicted very 
low sIFX level and ADA-positivity at follow-ups, with similar trend for RF-positivity (paper 
VI). 
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1 INTRODUCTION 
 
Rheumatoid arthritis (RA) is an autoimmune, chronic inflammatory disease characterised by 
painful joints and synovitis that can lead to a damage of cartilage and bone. It affects 
approximately 0.5-1% of total population (1) and occurs more often in women (60-86%) than 
men (2-4).  
Aetiology and pathogenesis of RA are not completely understood. However, recent advances 
in research have shown important role of interaction of some genetic susceptibility factors 
(the strongest being carriage of HLA-DRB1 and PTPN22), with environmental triggering 
factors such as smoking, infections and others (5-7). Better understanding the pathogenesis of 
RA would help to improve targeted treatment. However, the greatest challenge for this is the 
heterogeneity of the disease. Therefore, investigation of predictive and prognostic biomarkers 
is in high need, and identification of such factors could help discriminate subsets of patients 
with certain pathogenesis and predisposition of response to a specific therapy. 
 
1.1 PATHOGENESIS OF RHEUMATOID ARTHRITIS 
Rheumatoid arthritis is usually divided into two main subgroups in regard to auto-antibody 
status: seropositive and seronegative. Earlier, rheumatoid factor (RF) was the main 
autoantibody used for diagnosis and classification into sero-(RF) positive and seronegative 
disease. However, the commercial anti-cyclic citrullinated peptide (anti-CCP) test, used to 
measure anti-citrullinated protein antibodies (ACPA) that were discovered later than RF, 
show higher specificity for RA. The pathogenesis of seronegative RA is very unclear. The 
disease course of these patients is considered to be more heterogeneous compared with 
seropositive patients. In contrast, seropositive (anti-CCP positive) RA (2/3 of patients) has 
been studied in more detail and more clear picture has developed for the pathogenesis of anti-
CCP positive RA. First, the discovery that anti-CCP antibodies can develop in non-
symptomatic individuals several years before the onset of the disease attracted attention of 
many researchers to investigate the role of these autoantibodies in the pathogenesis. 
According to current theory (8, 9), development of ACPA starts from tissue located outside of 
the joints (for example, lungs or mucous membrane) leading to auto-antibody production. 
Shift of the process from extra-articular compartments to the joints is yet unclear. It is 
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Shift of the process from extra-articular compartments to the joints is yet unclear. It is 
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believed that expression of citrullinated epitopes on precursor osteoclasts attracts ACPA and 
triggers activation of these cells leading eventually to bone erosion. They also start producing 
IL-8 which binds to nociceptors in the joints triggering pain. IL-8 also may attract neutrophils 
(which is commonly seen in early arthritis) giving a start of the inflammation process 
(activation and migration of other inflammatory cells, vasodilation and production of pro-
inflammatory cytokines). Synovial membrane becomes infiltrated with macrophages, mast 
cells, T and B cells and plasma cells. These cells together with synovial fibroblasts produce 
pro-inflammatory cytokines (tumour necrosis factor (TNF), interleukin-6 (IL-6), IL-17, 
macrophage colony-stimulating factor (M-CSF), receptor activator of nuclear factor kappa-B 
ligand (RANKL)) and matrix enzymes that maintain and progress the inflammation in the 
joints, facilitate angiogenesis, cartilage destruction and osteoclastogenesis accelerating bone 
erosion (6). Histologically, RA synovium may have two phenotypes: diffuse, where 
lymphocytes are randomly infiltrated into synovial tissue without any structural formation and 
follicular, where T and B lymphocytes form clusters, so called germinal-like centres (10-12). 
It has been shown in RA patients that joints with follicular type of synovitis are at higher risk 
of destruction compared with diffuse synovitis (13). 
 
1.2 CLINICAL CHARACTERISATION AND OUTCOME OF RHEUMATOID 
ARTHRITIS 
1.2.1 Course and symptoms 
The diagnosis of RA is complex and is based on physical examination as well as laboratory 
immunological analysis of the presence of auto-antibodies towards IgG (RF-positive) and/or 
anti-CCP (anti-CCP-positive). Numbers of swollen and tender joints detected by 
rheumatologist together with molecular components of inflammation such as C-reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR) are other components of the 
diagnostic work-up. 
The course of RA may vary among individuals from mild to more aggressive and destructing 
features. RA may affect almost any join, however, joints of hands and wrists as well as 
forefeet are most usually affected ones (14, 15). At the onset, morning stiffness on the joints is 
often present. Most common symptoms are presented in Table 1. RA may in addition have 
extra-articular manifestations (Table 1). 
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Table 1. Clinical features of rheumatoid arthritis*
Symptoms Joint pain
Joint stiffness
Weakness
Deformity
Fatigue
Malaise
Fever
Weight loss
Depression
More common distribution Symmetrical
Distal
PIP
MCP
MTP
Wrist
Ankle
Extra-articular manifestations Skin (rheumatoid nodules)
Ocular (keratoconjuctivitis sicca, iritis)
Oral (salivaty inflammation)
Respiratory (pulmonary fibrosis, pleural
effusion, cricoarytenoid inflammation)
Cardiac (pericarditis, valvular nodule
formation, myocarditis)
Neurological (mononeuritis, nerve
entrapment, cervical instability)
Hepatic (increased aminotransferase
concentration)
Haematological (anaemia, 
thrombocytosis, leukocytosis, 
lymphadenopathy, slenomegaly, 
thrombocytopenia
Vascular (vasculitis)
MCP – metacarpophalangeal join, MTP – metatarsophalangeal joint, PIP – proximal 
interphalangeal join
* The table is adapted from Lee & Weinblatt, The Lancet 2001 and modified
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1.2.2 Disease activity measures 
Disease activity of RA is estimated using different clinical measures. Disease activity score 
based on examination of 28 joints and acute phase reactant (DAS28) is one of the routinely 
used outcome to monitor the disease (16). DAS28 is based on number of tender and swollen 
joints (TJC and SJC, respectively) of 28 examined joints (hands, wrists, elbows, shoulders 
and knees), patient’s global health on visual analogue scale (VAS), and CRP or ESR (Table 
2).  
 
Formulas for calculation of DAS28 based on CRP or ESR are expressed, respectively, as 
follows: 
DAS28-CRP = 0.56√(TJC28) + 0.28√(SJC28) + 0.36ln(CRP+1) + 0.014(GH) + 0.96 
DAS28-ESR = 0.56√(TJC28) + 0.28√(SJC28) + 0.70ln(ESR) + 0.014(GH) 
The scale of DAS28 helps to determine patient disease activity (Table 3). Cut-off values used 
for determining disease activity categories by DAS28-CRP or DAS28-ESR are most often the 
same. However, it has been shown that DAS28-CRP indicates somewhat lower values 
compared with DAS28-ESR (17-19). Fleischmann et al illustrated that threshold values of 
DAS28-CRP of 2.4, 2.9 and 4.6 corresponding to remission, low and high disease activity, 
respectively were equivalent to established cut-offs for DAS28-ESR (2.6, 3.2 and 5.1, 
respectively) (20, 21).  
Table 2. Disease activity measures in rheumatoid arthritis
DAS28-CRP DAS28-ESR SDAI CDAI
SJC + + + +
TJC + + + +
CRP + - + -
ESR - + - -
PatGH VAS + + - -
PatGDA VAS - - + +
PhysGDA VAS - - + +
CDAI - clinical disease activity index, CRP - C-reactive protein, DAS - disease activity score,
ESR - erythrocyte sedimentation rate, PatGH - patint global health, PatGDA - patient global
disease activity, PhysGDA - physitian global disease activity, SDAI - simplified disease
activity index, SJC - swollen joint count, TJC - tender joint count, VAS - visual analogue
scale.
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Clinical or simplified disease activity indices (CDAI or SDAI) are other measures similar to 
DAS28 (Table 2), but easier to calculate without computer (22). Both include TJC and SJC 
based on 28 joints, patient global disease activity VAS and physician global disease activity 
VAS. SDAI includes in addition CRP, too. Both CDAI and SDAI are calculated by simple 
summing all the components together and have a range between 0-76 and 0.1-86, 
respectively. 
 
1.2.3 Response criteria and functional assessment 
Change and improvement of patients health is measured by the change of disease activity 
measures. For example, the European League Against Rheumatism (EULAR) has developed 
response criteria based on the change in DAS28 as well as the value of DAS28 at the follow-
up (Table 4). According to the EULAR response criteria, patients are classified in no 
responders, moderate or good responders (23, 24). Similarly, the American College of 
Rheumatology (ACR) developed another criterion for evaluation of improvement during 
therapy. According to ACR criteria, patients achieving at least 20%, 50% or 70% of 
improvement in TJC and SJC, and in any 3 out of 5 other clinical parameters (pain VAS, 
patient’s global assessment, physician global assessment, ESR or CRP and functional 
questionnaire), are classified as having respectively ACR20, ACR50 or ACR70 response to 
the therapy (25). To assess functional activity, health assessment questionnaire (HAQ) is used 
(26). The HAQ is self-assessing tool which reflects the ability of patients to perform daily 
activities. For each question patient may receive scores: 0 (without any difficulty to perform), 
1 (with some difficulty), 2 (with much difficulty) and 3 (unable to perform). The total HAQ 
score is a mean of all obtained scores and therefore it has also the range between 0 and 3. 
Table 3. Disease activity categories
Categories DAS28 SDAI CDAI
High >5.1 >26.0 >22.0
Moderate 3.3-5.1 11.1-26.0 10.1-22.0
Low 2.6-3.2 3.4-11.0 2.9-10.0
Remissoin <2.6 <3.4 <2.9
Minimum value 0.49 0 0
Maximum value 9.07 86 76
CDAI - clinical disease activity index, DAS - disease activity score, SDAI - simplified disease activity 
index
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1.2.4 Imaging 
Apart from symptomatic and laboratory data, patients are evaluated by imaging techniques, 
such as X-rays, ultrasound and magnetic resonance imaging (MRI). The most routinely used 
is X-ray examination of joints. It helps to detect pathological changes, such as joint space 
width (JSW), and bone erosion, which are not detectable by physical examination. The 
difference in JSW at earlier and later time-points is called joint space narrowing (JSN).  
Assessment of JSN and bone erosion allows to monitor the dynamic of these changes during a 
given time-period, so called radiographic progression of joint damage (RP). These detected 
pathological changes are due to processes with shift of bone and cartilage turnover towards 
degradation. There are different scoring systems developed for the evaluation of bone and 
cartilage damages and disease progression (27). In 1971 Sharp developed a method of 
assessment of hands and wrists (28), which was later modified in 1985 and is known as 
standard Sharp method (29). In 1989 van der Heijde modified the standard Sharp scoring 
method of evaluation of hands and wrists (van der Heijde modified Sharp score), which 
includes also evaluation of feet and is based on bone erosions and JSN (30-32). Maximum 
erosion scores of hands and feet (per joint) are 5 and 10, respectively, and maximum JSN 
score is 4 per joint. The total van der Heijde modified Sharp score has a range between 0 and 
448 per patient. Another radiographic evaluation method of joints was introduced by Larsen 
in 1974 (33). This score also has been modified several times. Initially it contained also soft 
tissue swelling and periarticular osteoporosis which was removed during later modifications 
(34). The x-ray technique, however, has some limitations. For example, alteration in erosion 
size compared with previous picture might be due to slightly different position of joints and it 
indicates past events in patients, but no conclusion can be done for the current situation. 
Table 4. EULAR response criteria*
Improvement 
of DAS28
DAS28 at end time-point
>5.1 >3.2 - ≤5.1 ≤3.2
≤0.6 No No No
>0.6 - ≤1.2 No Moderate Moderate
>1.2 Moderate Moderate Good
DAS - disease activity score, EULAR - European League Against Rheumatism
* The table is adapted from van Gestel et al., 1996. and modified
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While radiography gives the possibility to detect pathological changes occurring on surfaces 
of hard tissue (bone and cartilage) and reflects the past of the patient, other methods such as 
ultrasound and MRI are able, in addition, to scan soft tissues of the inflamed joints. These 
tools can measure and illustrate pathological thickening of synovial membrane, tendons 
sheaths, ligaments and bursae, which indicates the degree of ongoing inflammation (35, 36). 
With the help of power Doppler and colour Doppler tools, ultrasound may also illustrate 
increased blood flow in the joints. In addition, MRI may detect pathological alterations in the 
bone, so called bone marrow oedema. Another useful aspect for both ultrasound and MRI is 
that they have been shown to identify subclinical inflammation, therefore are considered as 
important tools for early detection of pathological changes as well as monitoring patients in 
remission. 
A new method for imaging, fluorescent optical imaging (FOI), is being tested for its utility in 
early diagnosis and monitoring of patients with RA (37, 38). The method is based on a 
contrast media which is injected intravenously followed by scanning of hands for detection of 
the fluorescence intensity. The hyperaemic tissues give higher level of fluorescence intensity 
compared with normal (uninflamed). The method showed high correlation and agreement 
with other imaging techniques in one study (38), and weaker findings were in another study 
(39). A good agreement of FOI with ultrasound for detecting clinically silent synovitis was 
reported by Kisten et al (40). Higher sensitivity but lower specificity of FOI in RA patients 
compared with MRI or power Doppler ultrasound was observed by Krohn et al (41). 
 
1.3 THERAPY OF RHEUMATOID ARTHRITIS 
Since the aetiology and pathogenesis of RA is not fully understood, the treatment is 
challenging and is directed towards suppression of immune system by using corticosteroids 
and disease modifying anti-rheumatic drugs (DMARDs). Even introduction of biological 
DMARDs (bDMARDs) in treatment of RA did not result in 100% response of patients. The 
inconsistency of clinical outcome during therapies and presence of such a variation in therapy 
options highlights the heterogeneity of RA and a need of prognostic biomarker research. 
Based on results of many studies and current international guidelines, methotrexate (MTX) is 
the most recommended non-biological conventional DMARD (cDMARD) for first-line 
therapy (42, 43). MTX is a folate antagonist leading to reduction of pyrimidine and purine 
synthesis and stop in DNA replication; therefore it is being used in treatment of oncological 
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diseases. In RA, the beneficial effect of lower doses of MTX is not completely clear (44, 45). 
However, it is believed that its anti-proliferative action on lymphocytes leads to immune 
suppression. MTX can also inhibit JAK/STAT pathway (46), which is also a target of recently 
developed therapies. Taking into account that majority of pro-inflammatory cytokines are 
synthetized through this pathway, this property of MTX may explain its anti-inflammatory 
effect on RA. MTX was also found to lead to apoptosis of activated lymphocytes via 
increasing reactive oxygen species (ROS) (47-49). Another hypothesis of beneficial effect of 
MTX on RA patients is its ability to release endogenous adenosine, which binds its A2a 
receptor leading to immunosuppression (50, 51). 
In clinical practice of RA therapy approximately 30-40% of patients responds and improves 
their symptoms and lab outcome. According to EULAR and ACR recommendations, for those 
patients who do not achieve low disease activity or remission, the MTX therapy is intensified 
by adding other non-biological cDMARDs, such as sulfasalazine (SSZ) and 
hydroxychloroquine (HCQ) or biological DMARDs (bDMARDs) (42, 43). It has been proven 
by many investigations that the use of combinational cDMARD therapy is significantly 
effective than MTX monotherapy. For example, O’Dell and colleagues demonstrated that 
addition of SSZ and HCQ to MTX led to significantly better outcome compared with MTX 
monotherapy (52, 53). Similar result was observed by de Jong et al from tREACH trial (54). 
Biological therapy of RA became possible after Köhler and Milstein developed a method of 
monoclonal antibody production from hybridoma fused cells 4 decades ago (55). Today, there 
are 9 biological DMARDs used in RA care, of which 5 are TNF inhibitors (infliximab, 
etanercept, adalimumab, certolizumab and golimumab), one is against B lymphocytes (anti-
CD20; rituximab), one against T lymphocytes (abatacept), one against interleukin-6 receptor 
(IL-6 inhibitor; tocilizumab) and one IL-1 receptor inhibitor (anakinra) (56). The first study 
on biological therapy (anti-TNF) of RA was published in 1994 illustrating superiority of both 
higher and lower doses compared with placebo (57). The results from another study 
confirmed efficacy of addition of infliximab (IFX) to MTX monotherapy (58). In several 
randomized controlled trials significant effectiveness of etanercept was also proven 
(compared with placebo groups) on cDMARD-non-responders (59-61). The application of 
adalimumamb and its efficacy compared with MTX+placebo have been shown in numerous 
of trials (62-65). On 36 patients from a British double-blinded study, single intravenous 
infusion of certolizumab showed improvement by ACR20 and ACR50 in a dose-dependent 
manner (66). Other study applied sub-cutaneous administration of certolizumab, showing that 
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infusion of certolizumab showed improvement by ACR20 and ACR50 in a dose-dependent 
manner (66). Other study applied sub-cutaneous administration of certolizumab, showing that 
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400 mg dosing resulted in the best improvement compared with placebo or lower doses (67). 
Keystone and colleagues have demonstrated that certolizumab in combination with MTX was 
significantly more effective therapy option than MTX monotherapy (68). In an American 
study, RA patients with inadequate response to MTX received in addition double-blinded 
subcutaneously golimumab at two different doses or placebo (69). After 16 weeks of the 
initiation of the therapy, significantly higher proportion of patients achieved ACR20 response 
from golimumab group, compared with placebo. Similar results were reported from GO-
MORE clinical trial, where majority of patients who did not respond to cDMARD therapy, 
receiving subcutaneously golimumab achieved EULAR good/moderate response (70). 
Rituximab was developed for treatment of lymphocytic leukemia. In 2001 first results were 
published on the application of rituximab in few patients with RA (71). All of them achieved 
response according to ACR70 criteria during therapy. Later the effectiveness of rituximab was 
shown in other RA patietns (72-77). Anakinra have also been shown to be significantly 
superior to MTX+placebo in improving clinical and radiological outcomes (78-81). First 
background evidence that CTLA-4 pathway may be a reasonable target for therapy in RA was 
demonstrated in 1995, when symptoms of collagen-induced arthritis in rats were prevented by 
CTLA-4-Ig (82). In 2002 Moreland and colleagues published first evidence of CTLA-4-Ig 
safety and effectiveness on patients who failed DMARD therapy (83). Later came more 
studies confirming effectiveness of anti-T cell therapy (abatacept) in cDMARD and 
bDMARD non-responders (84-89). The high levels of IL-6 in autoimmune diseases led to 
more investigations on it ending up with development of antibodies targeting IL-6 receptor 
(90). First evidence of tocilizumab on RA patients was illustrated on a Japanese study by 
Nishimoto et al, where they demonstrated that patients with persistent symptoms achieved 
ACR20 response in dose-dependent manner (91). This was followed by a European multi-
center study where MTX inadequate responders were randomized to different doses of 
tocilizumab with or without MTX and MTX+placebo (92). Patients on tocilizumab 
monotherapy achieved better outcome than placebo group, but those on combination were the 
best. 
The relative effectiveness of combined cDMARD versus bDMARD therapy has been studied 
in several trials. However, it is not so clear which of these alternatives is better option. In the 
double-blinded randomized trials TEAR and RACAT, the edition of etanercept was generally 
not more effective than addition of sulfasalazine and hydroxychloroquine (triple therapy), 
establishing formal non-inferiority in the latter trial but identifying some clinical outcomes 
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that differed between the treatments (93, 94). Addition of infliximab for 6 months to triple 
therapy showed a clinically beneficial trend at 2 years compared with triple therapy+placebo 
group of patients from the NEO-RACo clinical trial (95). Following further yearly 
examination, however, the slope between the two arms merged closer – resulting in 
disappearance of the trend at 5 years. In the open-label randomized control trial SWEFOT, the 
addition of infliximab to MTX was significantly more effective after one year than escalation 
to triple therapy, but the effectiveness was no longer significant after two years (96). 
 
1.4 PREDICTIVE BIOMARKERS 
All these results were obtained on group level. However, it was shown in RACAT trial that 
some patients who failed to respond to combined cDMARDs did well after switching to 
bDMARD therapy, and some bDMARD-non-responders did better after they switched to 
combined cDMARD therapy (94). This suggests that cases are different and an individual 
approach is needed for more optimal therapy choice for each individual case. For this reason, 
predictive biomarkers, including demographic and molecular parameters have been studied 
extensively. 
 
1.4.1 Clinical and demographic factors as predictive tools for disease outcome 
Studies on different patient populations show that presence of several factors, including some 
of the risk factors for aetiology of RA, is indicator of more severe disease and poorer 
prognosis in RA. For example, smoking and female sex have been shown by many 
researchers to be poor prognostic factors for disease outcome in patients with RA on different 
therapies (97-99). Baseline DAS28, on which the treatment outcome is based, is considered 
one of the strongest and consistently illustrated predictors of response. Results from other 
baseline clinical and demographic factors are less consistent. 
 
1.4.2 Molecular biomarkers 
1.4.2.1 Auto-antibodies 
Autoantibodies are one of the earliest components of the disease. They arise several years 
before disease onset. Most commonly known and used are RF and anti-CCP antibodies, which 
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have diagnostic role. RF is found in many other autoimmune diseases, but anti-CCP is more 
specific for RA (100). Being positive for these autoantibodies (but more often for anti-CCP) 
have been shown in most of studies, relatively consistently, to predict higher risk of 
radiographic progression (100-106). 
Data regarding the association of RF and anti-CCP with subsequent clinical response or 
remission is more controversial. For example, in predominantly male US veterans with 
established RA, both RF- and anti-CCP-positivity (but more RF-positivity) were predictive 
for not achieving remission (107). In an Irish study, anti-CCP-positivity was associated with 
more lymphocytic infiltration in the synovium, lower proportion of EULAR response and 
higher proportion of radiographic progression (108). In a Thai study, being double-positive 
was an indicator of lower likelihood for achievement of remission at 1 year follow-up, 
compared with double-positive patients (109). Being positive for either of the auto-antibodies 
and having low likelihood of achievement of remission was shown by other researchers too 
(110-112). In contrast, several researchers found no association with auto-antibody status at 
baseline and subsequent clinical outcome (113-116). In addition, higher titers of anti-CCP 
antibodies have been shown to be predictors of better clinical outcome for some biological 
therapies (117, 118). The last observation makes anti-CCP antibody interesting possible tool 
for personalised therapy. 
 
1.4.2.2 Acute phase reactants 
C-reactive protein (CRP) is an inflammatory marker produced mainly by hepatocytes during 
inflammation. Secondary sources might be also monocytes, lymphocytes, adipocytes and 
some other cells (119, 120). Not being specific for RA, nevertheless, it has a diagnostic role 
for RA, but also is used to monitor patient inflammation intensity during therapy. Apart from 
being an inflammatory marker, CRP contributes in maintaining the inflammatory process, by 
affecting endothelial cells (upregulates VCAM-1 and E-selectin expression) and facilitating 
migration of leukocytes from blood stream to tissues (121). 
CRP is correlated with many symptoms of RA patients and is associated with subsequent 
radiographic progression (122-125). CRP might have a direct involvement in the joint damage 
process via increasing RANKL leading to osteoclatogenesis (126). 
Similarly to CRP, erythrocyte sedimentation rate (ESR) is an indicator of inflammation, 
correlates with CRP and symptoms of patients with RA, and its high level is associated with 
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radiographic progression (127-129). It measures rate of sedimentation of erythrocytes in mm 
per hour which depends on concentration of CRP and other inflammatory molecules in the 
blood. Apart from CRP, ESR is sex-specific and the threshold values for high category for 
male versus female is different (>20 versus >30 mm/hr, respectively). In a study, lower 
baseline levels of CRP (<3 mg/L), but not low ESR (<20 mm/hr) was independently 
associated with higher likelihood of remission and LDA during anti-TNF treatment (130). In 
contrast, another study demonstrated higher levels of both CRP and ESR (>10 mg/L and >30 
mm/hr, respectively) to be predictive for remission to TCZ (131). Similarly controversial 
results were observed by Navarro-Compan et al in their systematic literature review (132). 
Serum amyloid A (SAA) is another acute phase protein synthesised mainly by hepatocytes and 
is correlated with ESR, CRP and disease activity in patients with RA (133, 134). Extrahepatic 
sources, such as synoviocytes and chondrocytes of RA patients, have also been demonstrated 
(135, 136). In 1983, Chambers et al showed in 185 RA patients that all those with high SAA 
also had high CRP, however, 40% of patients with low CRP still had high SAA and they were 
similar clinically with those with high CRP (137). Similar result regarding SAA having higher 
sensitivity than CRP and ESR have been observed by others (138, 139). This may be caused 
by the method used (probably, SAA was measured with more sensitive method compared 
with CRP method). But if the discrepancy is true, both may be useful discriminative 
biomarkers since in the liver, CRP synthesis is driven by IL-6 and synthesis of SAA by IL-1 
(140). SAA has been shown to correlate with 28SJC, and induce expression of MMPs and cell 
adhesion molecules by synovial fibroblasts and endothelial cells, and facilitate leukocyte 
migration and angiogenesis (141-145). SAA but not CRP or ESR was also shown to correlate 
with cartilage turnover markers and predict 1 year radiographic progression (145). However, 
the pro-inflammatory property of SAA shown in-vitro previously was detracted by Björkman 
et al showing that natural SAA behaves differently from recombinant one (146). The reducing 
effect of anti-TNF therapy on SAA has been shown by Charles et al, however, not at that 
magnitude as on IL-6 and CRP (147). Tofacitinib was also shown to decrease both IL-6 and 
SAA (148). Decrease of SAA by golimumab+MTX during first 4 weeks might be predictive 
for response at 16 weeks in RA (149). SAA was higher in anti-CCP-positive RA patients 
compared with negative ones. Its better correlation with DAS28 compared with anti-CCP 
autoantibodies might make it better biomarker for monitoring RA patients (150). Higher 
levels of SAA were shown to be associated with a risk of CVDs and renal involvement in 
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patients with RA (151). SAA was more decreased by ETN+MTX than by conventional 
DMARDs (152). 
 
1.4.2.3 Inflammatory cytokines, metalloproteinases, growth factors and cell 
adhesion molecules 
In RA patients, there is a communication between immune cells and joint synoviocytes. One 
of the way of these communications occurs via cytokines. Cytokines are molecules that are 
released by some cells and affect the same or other cells via their specific receptors. The 
cytokines may have pro-inflammatory or anti-inflammatory role. In RA the equilibrium is 
shifted towards predominantly pro-inflammatory cytokines. 
Interleukin-1 (IL-1) is an inflammatory cytokine that is commonly produced by different cell 
types, including synovial fibroblasts in RA patients, and induces production of other 
inflammatory mediators including TNF-α. In RA, being produced by synovial macrophages 
and fibroblasts, IL-1 facilitates migration of the inflammatory cells to the joints. By this and 
inducing proteoglycan degradation, IL-1 plays a fundamental role in joint damage (153). 
However, Eklund et al has demonstrated that the association of baseline high IL-1β with the 
presence of erosions does not predict radiographic progression after initiation of DMARD 
therapy (154). Natural regulator of IL-1 is IL-1 receptor antagonist (IL-1Ra). In RA, the 
balance between production of IL-1 and IL-1Ra is altered (155-157). Treatment of RA 
patients with recombinant IL-1Ra (anakinra) have been shown to drop clinical disease activity 
and slow down radiographic progression (78, 79, 158). IL-1 was also shown to be associated 
with anaemia in RA patients (159). In 48 RA patients treated with MTX, having high levels of 
baseline IL-1β AND lower levels of IL-8 was associated with better clinical outcome (based 
on Ritchie-index, duration of morning stiffness and CRP) (160). Low level of IL-1β 
expression was observed in synovial tissue of patient with diffuse lymphoid infiltrates, which 
was associated with seronegative mild form of the disease course, while high expression of 
IL-1β was seen in patient with granulomatous synovial tissue – associated with extra-articular 
manifestation with nodules formation (10). Seitz et al showed that in patients with good ACR 
response (over ACR50) to 6 months of MTX, the ratio of IL-1Ra/IL-1β produced by PBMCs 
was significantly lower compared with non-responders (<ACR20) (161). Polish researchers 
showed that MTX+prednisone decreased serum levels of IL-1β and IL-6 but there was no 
association between the change and clinical response to the treatment (162). In 15 patients 
with RA and temporomandibular joint pain, high pre-treatment level of plasma IL-1β was a 
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poor prognostic factor for reduction of the pain after treatment with IFX (163). In another 
study on 51 RA patients, pre-treatment synovial expression of IL-1β did not differ between 
ACR20 responders and non-responders to IFX (164). Kayakabe et al, on the other hand 
demonstrated in white blood cells collected at baseline that their LPS-stimulation caused 
significantly higher production of IL-1β in 6-month post-anti-TNF treated responders 
(EULAR good/moderate) than non-responders (165). Baseline low or early (after 4 weeks) 
achievement of low serum IL-1β levels could predict response to tocilizumab after 1 year of 
therapy in advanced RA patients (166). 
IL-6, together with TNF-α, are considered as disease driving main molecules. IL-6 is a pro-
inflammatory cytokine that is produced by variety of cells including lymphocytes, fibroblasts, 
osteoblasts and endothelial cells. Its action occurs via both membrane bound IL-6 receptor 
(IL-6R) and soluble receptor (sIL-6R) affecting different cell types. In RA, IL-6 is increased 
in synovium and blood, and its level correlates with clinical disease activity and joint damage. 
Its proliferative effect on endothelial cells via increase of VEGF (167) suggests that IL-6 may 
contribute to angiogenesis in inflamed synovium of patients with RA. T- and B-cell responses 
are also require IL-6 stimulation. For example, IL-6 helps in differentiation of B cells into 
plasma cells and antibody production (168, 169), an event that is considered as a start point in 
the pathogenesis of RA. Moreover, a correlation was observed between IL-6 and RF titres 
both in synovial fluid and serum of seropositive patients (170, 171). IL-6 together with IL-1β 
also differentiate naïve T-cells into Th17 subset (172), which has been shown to have a 
fundamental role in autoimmune diseases. Expression of IL-6R on neutrophils suggests that 
IL-6 may play a role in neutrophil infiltration of inflamed synovium seen in RA. Indeed, 
increased IL-6, caused by co-culturing of RA fibroblasts with endothelial cells, and enhanced 
adherence of neutrophils to endothelium have been reported (173). Moreover, biopsies of 
synovial tissue from knee joints of 51 RA patients showed positive correlation between 
synovial IL-6 levels and infiltration of inflammatory cells in synovium (174). IL-6 trans-
signalling (interaction of IL-6 with sIL-6R) facilitates osteoclastogenesis via RANKL 
pathway, leading to bone resorption and joint destruction in RA while the osteoclastogenesis 
was inhibited by anti-IL-6R antibodies (175, 176). In collaboration with IL-1, IL-6 induces 
production of MMPs by synovial cells, leading to cartilage degradation (177). Via direct 
stimulation of hepatocytes, IL-6 may enhance acute phase response (178, 179) and production 
of hepcidin (180) – a peptide disturbing iron metabolism and causing anaemia, which is 
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commonly seen in RA. Fatigue, which is a common accompanying symptom in RA was also 
shown to be achieved in healthy volunteers after IL-6 injection (181). 
Methotrexate and other conventional DMARD treatment of patients with RA decreased levels 
of IL-6 (182, 183). Reduction of IL-6 level during first year of DMARD therapy was shown 
to correlate with clinical and radiographic outcome at 3 years (184). However, a study on 33 
RA patients treated with etanercept and 46 RA patients treated with rituximab did not show 
statistical difference in baseline serum IL-6 levels between responders and non-responders at 
3 months (185, 186). Similarly, a post-hoc analysis of 2 randomised control trials 
(CIMESRTA, N=150 and OPERA, N=180) failed to illustrate predictive capacity of baseline 
serum IL-6 level for clinical remission of radiographic progression during 2 and 5 years of 
follow-up (187). Surprisingly, another study of 73 established RA patients showed better 
clinical outcome from ETN therapy among those, who had higher baseline IL-6 level (188). 
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associated with response to TCZ (190). Moreover, they reported that patients with low, but 
not high pre-treatment IL-6 had more benefit from TCZ than from IFX therapy. Wang and 
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level of <5.16 pg/ml experienced more increase in sIFX level with more response compared 
with patients with ≥5.16 pg/ml level of serum IL-6 (194). This led to better 1-year drug 
survival after escalation in patients with low compared with high serum IL-6 level. A study on 
253 eRA patients showed that serum IL-6 levels were associated with radiographic 
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association became a non-significant trend when anti-CCP was included in the model. 
Gottenberg and colleagues, on the other hand, observed an independent from anti-CCP status 
association of baseline IL-6 with 1 year radiographic progression in 578 DMARD-naïve eRA 
patients (196). In another study of 173 RA patients urinary IL-6 showed independent 
prediction of RP at 1 and 3 years follow-ups (197). Patients with high levels of IL-6 had 
approximately 3 times higher risk of RP. This association remained even when looking in 
patients with low ESR only. In 88 newly diagnosed untreated RA patients pre-treatment 
higher IL-6 levels (>7.6 pg/ml, based on ROC curve) were associated with MRI-detected 
bone erosion during 1 year of follow-up (198). The association was independent from, and 
even stronger than seropositivity. Baseline low IL-6 levels, on the other hand, predicted MRI-
detected erosion repair. 
As mentioned earlier, TNF is another key, and mostly studied cytokine in pathogenesis of RA. 
Similar to IL-6 it affects many different cell types (pleiotropic) and is produced mainly by 
monocytes, macrophages, some T cells and other type of cells such as synoviocytes. Being a 
classical pro-inflammatory cytokine it can also express anti-inflammatory effects. Its action is 
expressed via binding one of the two receptors: TNF-RI (p55) and TNF-RII (p75). TNF-RI is 
expressed on many cell types, while TNF-RII mainly on immune and endothelial cells, as 
well as synoviocytes. TNF-RI has death domain and can activate caspase system leading to 
cell apoptosis, while TNF-RII lacks this domain. Both receptors may also induce cell 
proliferation and inflammation (199). A natural way of regulation of TNF-signalling is 
proteolytic cleavage of the membrane bound receptors, which still can bind TNF but do not 
induce intracellular signalling (decoy receptors) (200). Disability of cleavage of TNF-RI 
caused by mutation, has been shown to induce auto-inflammatory conditions (201). Signalling 
from TNF leads to production and secretion of many other inflammatory mediators such as 
IL-1, IL-6, GM-CSF and IL-8 (202-205). TNF facilitates also osteoclastogenesis and bone 
erosion through RANKL/RANK and other pathways, as well as cartilage degradation, 
angiogenesis and attraction of neutrophils (204). Blocking TNF in RA patients and mice with 
arthritis lead to decrease in nociceptive activity in the CNS detected by MRI already 24 hours 
after first injection of the anti-TNF drug (206). Notably, clinical and serological inflammatory 
signs were still unaffected. This suggests that TNF also contributes to pain feeling via directly 
affecting the CNS in patients with RA. 
TNF has been shown to be associated with histologically different disease phenotypes. For 
example, a study on 25 RA patients showed that subjects with follicular synovitis had 
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significantly higher levels of serum TNF compared with patients with diffuse infiltrates (207). 
A similar study on 47 RA patients by the same investigators showed similar results: higher 
serum levels of TNF, TNF-RI and TNF-RII in patients with follicular synovitis compared 
with diffuse histological type (208). In 50 RA patients, higher baseline production of TNF-RI 
from PBMC and higher serum levels of TNF-RII were observed in better responders to 6 
months of MTX therapy, when compared among 4 response groups (>ACR70 and ACR70-
50, ACR20-50 and <ACR20) (161). However, no significant association was observed for 
TNF. In an American study, pre-treatment sTNF levels were significantly higher in RA 
patients who did not respond to IFX therapy (assessed by Richie score index) compared with 
those who responded (209). In non-responders, increasing frequency of administration 
improved better clinical outcome than increasing the dose of IFX. A study in 60 RA patients 
demonstrated in multivariate analysis that synovial tissue mRNA level of TNF (among other 
cytokines) was predictive for joint damage progression (210). Contrary, a study of 99 serum 
biomarkers (including TNF) in 152 RA patients from GO-BEFORE trial did not reveal 
significant correlation between baseline levels of TNF or in the change of TNF at week 4 and 
radiographic damage progression at week 28 or 52 (211). Another study of 44 RA patients did 
not reveal any association of peripheral blood mRNA level at baseline with subsequent 
response to IFX at 22 weeks (212). Immunohistochemical examination of pre-treatment 
synovial biopsies of 143 RA patients indicated association of higher expression level of TNF 
with subsequent response (delta-DAS28>1.2) to IFX at week 16 (213). Responders also had 
higher number of infiltrated macrophages and T cells (potential sources of the TNF). In 33 
RA patients treated with ETN, serum level of TNF at baseline was not significantly different 
among responders (improvement in 3 of 4 ACR criteria) and non-responders at 3 months 
(185). In contrast, a study on 93 early RA patients from Japan, Sweden and USA 
demonstrated predictive capacity of pre-treatment serum TNF for response to ETN (higher in 
responders) (214). In 42 RA patients treated with non-biological DMARDs, baseline serum 
TNF was significantly lower in ACR20 responders than non-responders at 6 months (215). A 
Japanese study done on 327 RA patients from a double-blinded randomized control trial 
(RISING), (patients started IFX after MTX failure), illustrated a clear association of baseline 
plasma TNF levels with response (EULAR good or DAS28 remission or ACR-based) at 54 
weeks (216). In patients receiving the highest dose of IFX (10 mg/kg) significantly higher 
proportion of patients responded if they had lower baseline TNF levels (dose-response 
relationship among patients with low, intermediate and high levels of plasma TNF levels). It 
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was also observed that patients with high baseline levels of TNF had lowest level of serum 
IFX at 54 weeks, which was also associated with poorer outcome. 
IL-17, another cytokine, relatively recently have been shown to be involved in pathogenesis of 
autoimmune diseases. It is mainly produced by Th17 subset of CD4+ T cells and can be 
considered as opposing balance to Treg cells (217). IL-17 acts via its dimerised receptor 
leading to production of other inflammatory cytokines and chemokines, which could partially 
explain migration of neutrophils and monocytes (218, 219). Increased level of IL-17 has been 
reported in synovial fluid and serum of patients with RA (220, 221). Surprisingly, a nested 
case-control study has demonstrated that levels of IL-17 in pre-RA individuals (subjects 
without any symptoms and complains, who developed later RA) was significantly higher 
compared with the levels at the diagnosis (222). It can also induce osteoclastogenesis via 
RANKL pathway. The inflammatory and bone resorptive effect of IL-17 is synergised by the 
presence of TNF (219). In RA patients, serum IL-17 levels are highly correlated with disease 
activity, serum levels of TNF and CRP, and synovitis and bone erosions detected by MRI 
(221, 223). Nevertheless, IL-17 seems to be more important for pathogenesis of other 
inflammatory diseases such as psoriasis, since blockade of IL-17 or its receptor has been 
shown to have the best effect and were approved for psoriasis (219). 
In 60 RA patients from the DAMAGE study cohort, expression level of synovial tissue 
mRNA of IL-17 in combination with synovial mRNA of TNF or disease duration was shown 
to predict joint damage progression detected by MRI at 2 years of follow up (210). In 20 
active RA patients (10 treated with MTX and 10 – with adalimumab), Th17 cell levels in 
peripheral blood at baseline were associated with poor clinical outcome at 3 months (224). 
Levels of IL-17 were decreased in 25 RA patients after 30 weeks of treatment with 
MTX+IFX, but not in patients on MTX monotherapy (n=20) (225). A study in 48 RA patients 
treated with anti-TNF (adalimumab or IFX) demonstrated that baseline IL-17 levels were 
significantly higher in EULAR non-responders compared to moderate/good responders after 6 
months (226). In addition, among other Th17-related cytokines only IL-17 increased during 
the therapy in non-responders, while others decreased. A multivariate logistic regression 
analysis indicated IL-17 the only predictor of poor response. Similarly, Alzabin et al 
demonstrated in 2 groups of RA patients (n=24 and n=19) treated with anti-TNF, that in non-
responders there was significant increase of serum IL-17, while in responders the level was 
stable (227). Also there was an inverse relationship between proportion of Th17 cells at 
baseline and DAS28 at 4 week after the therapy. A double-blinded randomised control trial of 
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TCZ therapy in patients with inadequate response to DMARD therapy, demonstrated that 
baseline low serum level of IL-17 was associated with achievement of remission at 12 weeks 
(228). Of patients with low IL-17 levels, 48% achieved remission compared with only 17% of 
those with high IL-17 levels. 
In the joints of RA patients, a release of matrix metalloproteinases (MMPs) occur, that leads 
to digestion and destruction of bone and cartilage tissue. There are 23 different types of 
MMPs in the humans (from MMP-1 to MMP-28, where MMP-4, MMP-5, MMP-6 and MMP-
22 do not exist in the nomenclature) (229). Physiologically, the MMPs are proteases with 
Ca2+ or Zn2+ active sites. They are playing important role in degradation of components of 
extracellular matrix, such as collagen, during tissue remodelling at different stages of 
development of the organisms. Typical source of MMPs are cells of connective tissues of 
organs, fibroblast, for example, but also other cells: neutrophils, monocytes, macrophages and 
endothelial cells. Expression of MMPs may be increased by inflammatory cytokines, 
hormones and growth factors. 
In patients with RA, main matrix degrading members of MMPs are considered MMP-1 
(responsible for degradation of collagen type I, II, III, VII and X), MMP-3 (degrades collagen 
type III, IV, IX and X), MMP-7 (degrades collagen type IV and X), MMP-9 (degrades 
collagen type IV, V, VII and X) and MMP-13 (degrades collagen type I, II, III and IV) (230, 
231). It has been shown that MMPs, for example, MMP-1 and MMP-3, reflect clinical disease 
activity and structural damage of the joints in patients with RA (232-236). Their levels can 
also decrease during therapy, which is accompanied by clinical improvements (237, 238). 
MMP-7 has been shown to be linked with tissue remodelling in the lungs in patients with 
interstitial lung disease. In RA patients with interstitial lung disease, circulating levels of 
MMP-7 are significantly higher compared to patients without the complication (239). In a 
Japanese study of early RA patients, higher serum MMP-3 levels were associated with 
increased risk of joint damage (based on Larsen score) in the future (240). A study in RA 
patients revealed MMP-1 level more that MMP-3 level to be associated with development of 
erosions and stronger association of MMP-3 compared with MMP-1 with CRP (241). Early 
changes in MMP-3 caused by treatment using MTX or tenidap were predictive for later 
clinical response evaluated by DAS (242). Another study in 98 early untreated RA patients 
demonstrated that baseline serum MMP-1 and MMP-3 levels correlated with clinical 
improvements and joint damage progression (delta Larsen score) (243). Even patients with 
low CRP but high MMP-1 and MMP-3 showed higher risk of erosive disease during 
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subsequent 1 year. In patients without erosion at baseline, high level of MMP-3 was 
predictive for progression of Larsen score. A study in RA patients from ASPIRE cohort 
showed that baseline serum MMP-3 level as well as its reduction during first 6 weeks of 
therapy were associated with response (based on ACR criteria) at 54 weeks (238). Among 
other baseline markers, in a multivariate logistic regression model, only MMP-3 was 
predictive for clinical and radiographic outcome at 1 year. Similar predictive results of MMP-
3 (especially for radiographic progression) were seen by other researchers (244-248). 
However, a study of 45 RA patients treated with etanercept showed that reduction of MMP-3 
during 6 weeks of therapy did not differ between responders (patients in remission, n=10) and 
non-responders (n=35), while the decrease of another cartilage turnover biomarker, cartilage 
oligomeric matrix protein (COMP) was significantly greater in responders than non-
responders (249). Another controversial result was reported by Japanese researchers 
illustrating that baseline MMP-3 levels had a trend of higher level among progressors than 
non-progressors, while RF- and ACPA-positivity were significantly associated with 
subsequent radiographic progression (250). In contrast to this, a study in 118 RA patients that 
were followed up during 8 years, even though in a univariate analysis many baseline markers 
(including COMP and MMP-3) were associated with RP at 8 years of follow-up, a 
multivariate analysis revealed only MMP-3, anti-CCP-positivity and baseline radiographic 
damage of joints as independent predictors of radiographic progression (251). Significantly 
greater reduction in serum MMP-9 was observed in responders compared to non-responders 
to golimumab add-on therapy in MTX inadequate responders (149). In 114 patients with RA, 
an improvement of MMP-3 during first 4 weeks of therapy with adalimumab was 
independently from DAS28-CRP associated with remission at 1 year (252). 
Human cartilage glycoprotein-39 (YKL-40) is a protein produced by chondrocytes, synovial 
fibroblasts, macrophages and neutrophils. It is considered as a chitinase enzyme with lost 
enzymatic activity towards chitin. Increased levels of serum YKL-40 were linked with 
inflammation and tissue remodelling, however, still the physiological role of YKL-40 is 
unclear (253). In synovium of patients with RA, compared with healthy controls YKL-40 is 
also elevated. Even though serum levels are significantly lower than that in synovium, there is 
a clear correlation between them. Moreover, both synovial and serum levels reflect disease 
severity and degree of joint damage in RA (253, 254). 
In a study of 191 early RA patients treated with DMARDs (MTX or SSZ), baseline serum 
levels of YKL-40 were not associated with radiographic progression during subsequent 3 
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severity and degree of joint damage in RA (253, 254). 
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levels of YKL-40 were not associated with radiographic progression during subsequent 3 
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years of follow-up (255). Similar non-association of baseline YKL-40 with 2 years 
radiographic progression was observed in another RA group treated with adalimumab, even 
though it was correlated with CRP, MMP-1 and MMP-3 (236). Similarly, a Finish study 
confirmed unpredictability of baseline serum YKL-40 levels for subsequent radiographic 
progression, however, correlation with inflammatory markers was obvious (256). A study in 
136 RA patients also showed no predictive value of baseline YKL-40 levels for RP during 
subsequent 5-10 years (257). And finally, a study in patients from CIMESTRA trial (n=150) 
confirmed non-predictive ability of serum YKL-40 for RP, but also for achievement of 
clinical remission (187). In the same study, the authors confirmed these results in a validation 
cohort from OPERA trial (n=180). 
Leptin is a lipid hormone produced by white adipose tissue and is known as a regulator of 
appetite and energy expenditure via acting on hypothalamus and inhibiting production of 
neuropeptide Y. Its production is positively correlated with body weight and decreases 
appetite in order to avoid obesity (258). Leptin has been found to be related also to 
inflammation and immune response. This relationship is two-sided: pro-inflammatory 
cytokines increase leptin level, as well as leptin induces production of pro-inflammatory 
cytokines and activates phagocytosis (259). Leptin’s pro-inflammatory role via impact on 
innate and adaptive (mostly T cells) immune systems has been shown in many studies (260). 
In RA, synovial leptin level is significantly lower than in serum, and RA patients have 
significantly higher level of leptin than healthy controls (261). However, the data about leptin 
in RA is quite controversial among different studies, as discussed in Tian et al review article 
(260). Some studies showed protective role of leptin for radiographic progression, while 
others failed to illustrate that. Similarly, a controversial results about effect of anti-TNF 
therapy on serum leptin is discussed in the same review, indicating no change in the majority 
of studies, however, some studies observed increase in leptin level. Probably, its high 
dependence on proportion of white adipose tissue makes it difficult for any conclusion. In a 
group of consecutive RA patients treated with non-biological DMARDs, baseline leptin was 
associated with higher DAS28 at 6 months (262). In patients with normal BMI, the 
association hold also for 1 and 2 years outcome. The complexity of results regarding leptin as 
reflector or predictor of disease activity could be explained by its dependence on other 
parameters, such as proportion of white adipose tissue. This in its turn is affected by body 
weight and gender. Smoking should also be considered when investigating leptin in RA 
patient, since it suppresses leptin production (263). 
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Another adipokine, resistin, which was initially thought also to be produced mainly by 
adipocytes, and to cause insulin resistance, later has been shown to be produced by peripheral 
blood mononuclear cells and more to be involved in subclinical inflammation processes and 
autoimmune diseases (264). In RA, levels of resistin in both synovial tissue and serum is 
elevated compared to healthy controls and even compared to patients with osteoarthritis and 
spondyloarthropathy (265). Resistin is produced by different immune cells on response to 
inflammatory cytokines and induces homing of endothelial progenitor cells to the joints, and 
overexpression of VEGF (266). Consequently, resistin might be involved in the process of 
angiogenesis in RA. Resistin was also shown to correlate with disease activity markers such 
as serum TNF and CRP, RF anti-CCP and joint radiographic data (267). Anti-TNF treatment 
decreases serum level of resistin in RA patients which is associated with post-treatment 
reduction of CRP and TNF (268). However, as usual with the majority of biomarkers, there 
are some studies not confirming above mentioned results for resistin. For example, Otero et al 
showed that leptin, adiponectin and visfatin levels but not resistin levels were significantly 
different in 31 RA patients compared to 17 healthy controls, and that the mentioned three 
biomarkers but not resistin correlated with CRP (269). 
For prediction of radiographic progression over 4 years, baseline resistin levels had no value 
(195, 270). Regarding clinical disease activity only correlations have been published between 
resistin and different disease activity measures from the same time-points, but no predictive 
results have been reported. 
Some of characteristic features of RA are hyperplasia of synovial fibroblasts leading to 
invasion of the synovial tissue, hypoxia and neovascularisation, leading to pannus formation. 
Epidermal growth factor (EGF) is a known marker for tumour tissue since it induces 
neoplastic alteration. It also is responsible for angiogenesis. Similarly to tumour, in RA, EGF 
is upregulated. Both synovial and serum concentrations are higher compared to healthy 
individuals, but even compared with osteoarthritic patients (271-273). Hyperplasia of synovial 
fibroblast may partially be explained by increased EGF, since upregulation of EGFR 
expression on these cells is reported in RA patients. A significant correlation with 
neovascularisation also indicates its role in the latter. A mouse model of collagen induced 
arthritis demonstrated that inhibition of EGFR reduces symptoms of the arthritis, and 
proliferation of synovial fibroblasts and osteoclasts, indicating indirectly that EGF and its 
signalling may play an important role in the pathogenesis of RA (273). These results were 
replicated by another research group (274). 
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Early changes in serum EGF levels were found to be positively correlated with later changes 
in total van der Heijde-Sharp radiographic score in early RA patients on MTX monotherapy, 
but not in patients on MTX+golimumab (211). 
Vascular endothelial growth factor (VEGF) is the main angiogenic factor that has been 
considered in RA patients. It is produced by macrophages, synovial fibroblasts, platelets and 
endothelial cells (275). Similar to EGF, levels of VEGF have been shown to be higher in 
synovial tissue, fluid and sera of RA patients compared with healthy people or osteoarthritis 
patients (276). Fast growth of fibroblast-like synoviocytes causes hypoxic environment in the 
arthritic joints which activates angiogenesis via upregulation of VEGF (277). Blocking 
VEGFR on the other hand improved symptoms in collagen induced arthritis in mice (278). In 
RA, serum levels of VEGF have been shown to correlate with inflammatory markers and 
clinical disease activity symptoms such as CRP, tender joint count and pain. Pro-
inflammatory cytokines such as TNF, IL-1, IL6 and others, induce production of VEGF and 
therapy of patients with RA (both non-biological and biological DMARDs) decreases the 
serum level of VEGF and reduce newly built capillaries, but not normal blood vessels (275, 
277, 279). 
Increased levels of serum VEGF is associated with radiographic progression at 1 year of 
follow-up and reduction of sVRGF levels – with clinical improvements (280). Another study 
in two different cohorts of RA patients: CIMESTRA (N=150) and OPERA (N=180), showed 
correlation of VEGF with DAS28, but could illustrate predictive ability of VEGF for 
radiographic progression at 2 years of follow-up only for OPERA cohort, and for neither of 
the cohorts was VEGF predictive for clinical remission (187). 
Migration of the leukocytes from blood stream through endothelial layer to the affected tissue 
is one of necessary and indispensable processes for inflammatory response. The cytokines that 
are released from macrophages and other cells in the damaged tissue play a crucial role in 
recruiting the leucocytes. The process of migration of the inflammatory cells occurs due to 
changes on the surface of both the leukocytes and endothelial cells, which enables the former 
to become more adherent to the later. In this way the leukocytes start rolling on the blood 
vessel walls before the migration occurs. Stickiness of the cells is ensured by adhesion 
molecules that are overexpressed on the membrane, induced by inflammatory cytokines. 
Here, vascular cell adhesion molecule-1 (VCAM-1), among other is known to have an 
important role for binding integrins on the surface of the leukocytes. VCAM-1 is mainly 
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expressed on endothelial cells, but in inflamed environment its expression is detected on other 
cells such as tissue macrophages, dendritic cells, bone marrow fibroblasts and others (281). 
The importance of VCAM-1 in RA has been shown by many researchers, which is discussed 
in a review article by Kong et al (281). Serum level of soluble VCAM-1 is higher compared 
with healthy controls. Treatment with DMARD or biological medications decreases its level. 
Blocking VCAM-1 with monoclonal antibodies dramatically reduces signs of arthritis in the 
CIA moue models. However, when studying expression of different molecules on synovial 
membrane in 40 RA patients treated with non-biological DMARDs, an association was found 
between decrease in expression of other cell adhesion molecules, but not VCAM-1 on the 
synovial biopsies and improvement of clinical outcome (282). Macias et al demonstrated in 
RA patients that after MTX monotherapy, responders had significantly lower serum VCAM-1 
compared with incomplete responders (283). In 143 RA patients failing two DMARD 
therapies and starting IFX, expression of VCAM-1 in joint tissue sections, detected by IHC 
just before IFX start, did not differ between subsequent responders and non-responders at 
week 16 of IFX therapy (213).  
 
1.4.2.4 Multi-biomarker disease activity score 
RA is a very heterogeneous disease. In addition to this, different clinical trials address 
different questions, using different inclusion and exclusion criteria, which make patients to 
differ significantly between studies. And finally, the stage of disease could affect variations in 
pathological processes and treatment responses. These are important facts that one needs to 
consider when trying to replicate biomarker research on different RA cohorts. The abundance 
of discrepant results for the same biomarker could be explained by these factors. Therefore 
using one biomarker would probably always lead to failure in validation of results in a 
different cohort. 
A multi-biomarker disease activity (MBDA) score (Vectra® DA) is a blood-based test that has 
been developed as a tool for monitoring of disease activity in complement to existing disease 
activity measures such as DAS28 and radiographic imaging of the joints (284, 285). It has 
been developed by a multi-step process, starting from identification of 130 candidate 
molecules from literature searches, and narrowing down during the further prioritisation 
studies to 24 candidate biomarkers (286). The 24-biomarker-based disease activity score 
already correlated with DAS28 and radiographic progression. At the next stage of 
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development, some biomarkers were eliminated because of their high dependence on the 
conditions of the analyses, resulting in a high variability, and other reasons. After the final 
optimisation and algorithm training, 12 biomarkers remained in the model. The algorithm of 
the final MBDA score is calculated from serum concentrations of the following 12 
biomarkers: VCAM-1, EGF, VEGF, IL-6, TNF-RI, MMP-1, MMP-3, YKL-40, leptin, 
resistin, SAA and CRP. The MBDA score is well correlated with DAS28 and other disease 
activity measures, and has a scale between 1 and 100 indicating from the lowest to the highest 
disease activity, respectively (284, 287, 288). Its validated cut-offs generate categories of 
patients in LDA (MBDA score <30), moderate disease activity (MBDA score 30-44) and high 
disease activity (MBDA score >44). Being correlated with disease activity and inflammatory 
markers, the MBDA score seems to complement them as shown in the study by Lee et al 
(289). In their study it was shown that many RA patients with CRP<1.0 mg/dl, had 
moderate/high MBDA score and there was a linear association between SJC and the MBDA 
score but not CRP. The dynamic of the MBDA score also reflects the change of disease 
activity measured by other clinical methods. These associations were independent of a type of 
anti-TNF treatment (IFX, adalimumab or etanercept) (290). However, assessment of the 
MBDA score in RA patients treated with tocilizumab should be interpreted cautiously, since 
tocilizumab causes increase of serum IL-6 leading to increase in the MBDA score, while 
decreasing other disease activity indices (291). 
Predictive studies for the MBDA score have also been conducted by many researchers. For 
example, the MBDA score predicted progression of joint damage detected by radiographs, 
ultrasound or MRI in different RA studies (292-296). However, Bakker et al demonstrated 
that even though the MBDA score was well associated with disease activity, it could not 
predict subsequent radiographic progression (287). It was also shown that the MBDA score 
predicting relapse in RA patients that were in sustained remission (297). The prediction was 
independent from ACPA and their combination increased associations: in patients with low 
MBDA score and negative ACPA status only 13% relapsed, while among those with higher 
MBDA score and positive ACPA status 76% relapsed. In the DRESS study, in patients in 
remission and tapering anti-TNF therapy the MBDA score did not predict flare or successful 
tapering/discontinuation, however, did predict flares in usual care patients (298). In contrast to 
these associations mentioned above, another Dutch study (POET) has demonstrated that 
patients in LDA and tapering anti-TNF treatment, high baseline MBDA score predicted flare 
at 12 months (299). Another controversial finding was reported in a study of RA patients 
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treated with abatacept or adalimumab, where the MBDA score was correlated with DAS28-
CRP and CDAI only at baseline, but not at follow-ups (300). Moreover, the researchers 
reported that CDAI was better associated with radiographic progression outcome than the 
MBDA score. To summarise, it is worth to mention that for interpretation of the MBDA 
score, consideration of the age, and BMI of the patients have an important role (301). 
 
1.4.2.5 Serum level of therapeutic bDMARD and anti -drug antibodies 
Prediction of response to bDMARDs should have been more clear compared to non-
biological DMARDs, because of a clearly defined target. However, the prediction is 
complicated by the immunogenicity of the therapeutic drugs. The structure of the bDMARD 
molecules triggers the immune system of the patients to respond and generate anti-drug 
antibodies (ADA). Most of the cases these antibodies are neutralising (binding to the target-
binding region of the drug molecule). But even non-neutralising antibodies may create 
immune complexes leading to accelerated clearance of the bDMARD from the organism of 
the patient. In any of the cases the immunogenicity will lead to decrease of therapeutic drug 
concentration in the blood consequently leading to loss of efficiency. Infliximab is considered 
to be the most immunogenic (302) because of its not fully humanised molecular structure 
(TNF-binding site is from mouse). 
According to different studies the proportion of RA patients developing ADA to IFX 
fluctuates between 12% and 54% (303-310). Low drug levels in the blood of patients was 
associated with ADA-positivity (305, 307, 311). In addition, both low drug level and ADA-
positivity have been associated with poorer clinical outcome and worse drug survival 
compared with patients with high drug level or ADA-negative patients (303, 312-315). These 
observations suggest that monitoring of patient bDMARD level in the blood as well as 
analysis for ADA may provide essential information to the rheumatologist for optimisation of 
biological therapy in patients with RA. Garces and colleagues, for example, have suggested 
an algorithm of treatment of RA patients with bDMARDs based on the availability of 
information about current disease activity, serum trough level of the therapeutic bDMARD 
and ADA status (316). Such studies need validation on different RA cohorts using the same 
methods of analysis for serum drug levels and ADA status. Confirmation of the importance of 
the blood drug monitoring and ADA status for achievement of good clinical outcome would 
improve dramatically the healthcare in rheumatology. 
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In conclusion, RA, as a very heterogeneous disease with unclear aetiology and pathogenesis, 
is challenging for investigation. The optimal therapy is different for individuals; therefore 
conducting biomarker studies has an important role in discovery of individuals with different 
mechanisms of disease. In biomarker discovery a huge role plays the method and patients 
inclusion criteria since different methods of measurement of biomarkers, serum drug levels 
and anti-drug antibodies may yield very different results, likewise whether patients were on 
different therapies during several years or they are newly diagnosed, treatment-naïve early RA 
patients. Considering these factors in the investigations will provide more reliable data for 
description of predictors in RA populations. 
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2 AIM OF THE THESIS 
2.1 OVERARCHING AIM 
In the presence of challenge of optimal therapy choice and to predict disease course and 
outcome, the general aim of this PhD thesis was to investigate different blood proteins related 
to inflammation and immune system as predictors of disease outcome in patients with early 
RA. The exploration of predictors will contribute in identifying patient phenotypes with 
certain characteristics, which will enable the best personalised approach for each individual 
patient. 
 
2.2 SPECIFIC AIM 
The study-specific aims of this PhD projects were: 
1) For Study I 
a) Using the MBDA score, to identify patients at high versus low risk of subsequent joint 
radiographic progression. 
 
2) For Study II: 
a) Using the MBDA score at the time of treatment escalation, to identify patients at 
higher chance of response to IFX or conventional triple therapy (TT), after failure to 
MTX monotherapy. 
 
3) For Study III: 
a) Using individual biomarkers that comprise the MBDA score, to identify patients at 
higher versus lower chance of response to MTX monotherapy in early RA. 
b) Using affinity proteomics analyses to explore serum biomarkers that could identify 
patients at higher versus lower chance of response to MTX monotherapy in early RA. 
 
4) For Study IV: 
a) In early RA patients randomised to IFX+MTX therapy, to study relationship between 
serum IFX concentration, anti-drug antibodies (ADA) and clinical outcome. We also 
aimed to investigate baseline predictors for low serum IFX level and development of 
ADA. 
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3 MATERIALS AND METHODS 
3.1 PATIENT POPULATION 
For all study projects materials from Swedish Farmacotherapy (SWEFOT) trial were used 
(96, 317). The SWEFOT is a randomised-controlled clinical trial of DMARD-naïve, early RA 
patients (N=493). Newly diagnosed RA patients with active disease (DAS28 >3.2), symptom 
duration <1 year and age >18 years were included to the trial and started MTX monotherapy 
for 3 months duration. Patients achieving low disease activity (DAS28 ≤3.2) after 3 months 
continued the MTX therapy and those patients with DAS28 >3.2 were randomised to 
conventional triple therapy (MTX-sulfasalazine+hydroxychloroquine) or to biological therapy 
(MTX+IFX). The patients were followed up 2 years from the inclusion into the trial (Figure 
1). 
  
Figure 1. SWEFOT trial design 
This thesis is composed of four Study projects (Figure 2) and for each of the project a subset 
of patients was selected based on availability of data needed for the specific study aim. For 
the MBDA score projects, totally serum samples of 302 patients were analysed at baseline, of 
whom 290 were analysed at 3 months and 190 (only randomised patients) at 1 year. However, 
each of the substudies done on the MBDA score data, different number of these 302 patients 
were selected (see below for details in each individual project). 
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Figure 2. Plan of PhD projects 
 
3.2 STUDY I 
In Study I the MBDA score was investigated for prediction of subsequent radiographic 
progression. In the first paper of the Study I (paper I), the MBDA score of 235 patients at 
baseline were analysed for prediction of RP at 1 year. For the second paper (paper II) the 
MBDA scores at baseline, 3 months and 1 year were analysed in 220, 205 and 133 patients 
respectively for prediction of RP between baseline and 1 or 2 years and between 1 and 2 
years. For the RP, van der Heijde modified Sharp scores (SHS) were used. An increase of the 
SHS >5 was considered as RP. Cut-offs of >3 and >0 were also compared. The Proportion of 
patients with RP were compared among categories of the MBDA score (low: <30, moderate: 
30-44 and high: >44) and other disease activity measures (CRP, ESR and DAS28). In the 
second paper (paper II) not only MBDA score at a certain time-point, but also the dynamic of 
it from baseline to 3 or 12 months and from 3 to 12 months was assessed for prediction of RP 
from baseline to 1 or 2 years and from 1 to 2 years. 
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3.3 STUDY II 
In the Study II, which was published in paper III, the association of the MBDA score at 3 
months with second-line treatment outcome at 1 year was assessed. As treatment outcome 
measures, low disease activity and EULAR good response were used. For patients with 
missing clinical data at 1 year, last observation carried forward (LOCF) was applied. In this 
study 157 patients who failed to achieve LDA on MTX monotherapy were included. Of the 
157 patients, 75 were randomised to conventional TT and 82, to IFX therapy. Apart from 
validated categories for the MBDA score (low, moderate and high), new cut-offs were also 
applied based on receiver operating characteristic (ROC) curve analysis for dichotomisation 
of patients into high and low MBDA score categories. The proportion of patients achieving 
LDA or EULAR good response between groups with low versus high MBDA categories were 
compared for each therapy group separately and then the results were compared between the 
therapy groups. As reference predictors CRP, ESR and DAS28 at 3 months were compared. 
 
3.4 STUDY III 
In the Study III protein biomarkers at baseline were analysed for association with treatment 
outcome (LDA and EULAR good response) at 3 months in RA patients treated with MTX 
monotherapy. 
 
3.4.1 Study IIIa 
Here we investigated the MBDA score and comprising it 12 individual biomarkers at baseline 
as predictors of achievement of LDA or EULAR good response at 3 months. Two hundred 
and ninety-eight patients were included of whom, 104 achieved LDA and 101, EULAR good 
response. Four biomarkers that were significantly different between patients who achieved 
and did not achieve LDA.  They were analysed by ROC curve analysis for dichotomisation 
into low and high categories. Then the proportion of patients achieving treatment outcome 
was assessed. The four biomarkers were also combined into a combined biomarker score 
resulting in a scale between 0 and 4 and indicating respectively, the association with lowest to 
highest risk for not achieving the treatment outcome. The combined biomarker score was also 
added to a predictive matrix together with previously established demographic predictors such 
as sex and age. 
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3.4.2 Study IIIb 
In this study 177 target proteins were assessed at baseline in 135 selected RA patients as 
predictors of outcome of MTX monotherapy at 3 months. In univariate analyses, eight 
proteins differed between patients who achieved (n=50) and did not achieve (n=85) LDA at a 
level of p-value <0.001. In a multivariate analysis, only two were significantly different. 
These two proteins were analysed by ROC curve and were dichotomised into low and high 
categories with subsequent comparison of proportion of patients achieving treatment 
outcomes. The two proteins were combined then generating four categories: low/low, 
low/high, high/low and high/high, and the proportions of patients achieving treatment 
outcome were assessed between these categories. In this study, an attempt of reproducing the 
results for one of the proteins was done in another RA cohort (COMBINE, N=74). 
 
3.5 STUDY IV 
In the Study IV, 101 patients who failed MTX therapy and were randomised to MTX+IFX 
treatment were included for investigation of serum level of IFX (sIFX), anti-drug antibodies 
(ADA) and their relation with treatment outcome (LDA or remission), as well as to identify 
baseline predictors of low sIFX level and ADA development. The serum samples were 
analysed at 3 (missing n=8), 9 (missing n=6) and 21 months after initiation of IFX treatment. 
All 289 serum samples were analysed for sIFX level, but only samples with sIFX 
concentration <0.2 μg/ml (n=64) were analysed for ADA-positivity (Figure 3). 
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Figure 3. Schematic illustration of serum samples analyses for IFX and ADA in 101 patients from the 
SWEFOT trial 
Patients who were ADA-positive at least ones during the follow-up, were considered as ever 
ADA-positive and their baseline parameters were compared with parameters of never ADA-
positive patients. 
 
3.6 SERUM SAMPLE ANALYSES 
Serum samples for all study projects were analysed out of our facility by different laboratory 
personals. 
3.6.1 Analyses of 12 proteins and the MBDA score generation 
The serum samples were shipped to Crescendo Bioscience, South San-Francisco, CA, USA 
for the analysis. The individual 12 biomarkers were analysed by an 
electrochemiluminescence-based multiplex immunoassay on the Meso Scale Discovery 
Multi-Array platform. The MBDA score was calculated based on concentration of the 12 
biomarkers using Vectra® DA trained algorithm, which is a patent of Crescendo Bioscience 
and is undisclosed. 
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3.6.2 Analyses of serum proteins for the affinity proteomics project 
Serum samples were sent to Science of Life Laboratory (SciLifeLab) for the analysis of 177 
proteins, which was done in Prof. Peter Nilsson’s lab. The 177 target proteins were selected 
based on previous studies in inflammatory and autoimmune diseases. These proteins were 
analysed using 380 antibodies from Human Protein Atlas. In addition four controls were also 
used: anti-human IgG and anti-albumin as positive controls, and rabbit IgG and beads without 
any proteins as negative controls. The levels of the proteins were expressed in median 
fluorescent intensity (MFI). 
 
3.6.3 Analysis of sIFX levels and ADA 
Both sIFX and ADA were measured using in-house validated ELISA methods that are used at 
Swedish University Hospitals. For sIFX, plates coated with TNF were used. For detection of 
ADA, only samples with <0.2 μg/ml sIFX levels were analysed, since IFX interferes with the 
analyts and gives false-positive results. For detection of ADA, competitive ELISA was used: 
the analyte, which is also IFX, is incubated with TNF-coated plate followed by adding serum, 
whose unbound ADA competes and displaces with TNF and binds to the analyte. 
 
3.7 STATISTICAL ANALYSES 
For non-parametric variables Mann-Whitney U test was used for all study projects. In all 
projects also proportion of patients were compared between two different groups, for which 
Chi-squared or Fisher’s Exact test were used. In Study III, the homogeneity of odds ratio was 
tested by Breslow-Day test. For prediction analyses, uni- and multivariate logistic regression 
analyses were used (Study I, III and IV). In Study IIIb, of 380 variables (for 177 proteins), 
those with p-value <0.001 in the univariate analyses were included in multivariate logistic 
regression model. For cut-of determination, ROC-curve analysis was applied in Studies II and 
III. The cut-of levels were based on values corresponding to the highest sum of sensitivity and 
specificity. 
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4 RESULTS AND DISCUSSION 
4.1 STUDY I (PAPERS I AND II) 
In Study I, we investigated the MBDA score as a predictor of RP. The selected patients for 
this study did not differ significantly by their baseline parameters from the entire SWEFOT 
population. As it was expected, the MBDA score correlated with disease activity markers 
such as DAS28 and CRP (Figure 4).  
 
Figure 4. Correlation of the MBDA score with DAS28 (A) and CRP (B) at baseline. 
 
4.1.1 Discordance between the MBDA score and other disease activity markers 
The categories of these markers, however, had some discrepancies (Figure 5). For example, of 
235 patients 5, 29 and 201 had low, moderate and high MBDA scores, however, of 71 
patients with low CRP 42 had high and 24 had moderate MBDA scores and about quarter of 
patients with low CRP but high MBDA had RP at 1 year (Figure 5C). Patients with low 
MBDA score (n=5), on the other hand, had low CRP and none of them progressed. No patient 
had low DAS28 at baseline, since it was an exclusion criteria for the SWEFOT trial. In total, 
low/moderate versus high categories of the MBDA score at baseline discriminated patients at 
very low versus high risk of subsequent RP at 1 year (3% and 21%, respectively, p=0.012; 
Figure 5D). 
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Figure 5. Cross-tabulation of all analysed patients and subset with rapid radiographic progression 
over one year, by baseline disease activity measures. The denominator in each cell represents the 
number of patients cross-classified by baseline MBDA and DAS28-ESR (A), baseline MBDA and 
DAS28-CRP (B) and baseline MBDA and CRP (C) disease activity scores. The numerator in each cell 
represents the number of patients with radiographic progression at one year. Figure D illustrates 
radiographic progressors for MBDA low, moderate and high score groups (%). Radiographic 
progression at one year is defined by increase in SHS > 5 compared to baseline. 
 
4.1.2 The MBDA score in prediction of RP 
In bivariate analyses, the MBDA score was independently of other risk factors such as RF, 
ACPA and sex, predictive for radiographic outcome of the joint damage during 1 year of 
follow-up (Table 5). In multivariate logistic regression analysis, high MBDA score at baseline 
compared with low/moderate, was 3.9 times more associated with higher risk of RA at 1 year 
(adjusted for sex, symptom duration, baseline erosions, current smoking and HAQ score). 
This was similar with results from the BeSt study, however, for a univariate analysis (for high 
36 
 
 
Figure 5. Cross-tabulation of all analysed patients and subset with rapid radiographic progression 
over one year, by baseline disease activity measures. The denominator in each cell represents the 
number of patients cross-classified by baseline MBDA and DAS28-ESR (A), baseline MBDA and 
DAS28-CRP (B) and baseline MBDA and CRP (C) disease activity scores. The numerator in each cell 
represents the number of patients with radiographic progression at one year. Figure D illustrates 
radiographic progressors for MBDA low, moderate and high score groups (%). Radiographic 
progression at one year is defined by increase in SHS > 5 compared to baseline. 
 
4.1.2 The MBDA score in prediction of RP 
In bivariate analyses, the MBDA score was independently of other risk factors such as RF, 
ACPA and sex, predictive for radiographic outcome of the joint damage during 1 year of 
follow-up (Table 5). In multivariate logistic regression analysis, high MBDA score at baseline 
compared with low/moderate, was 3.9 times more associated with higher risk of RA at 1 year 
(adjusted for sex, symptom duration, baseline erosions, current smoking and HAQ score). 
This was similar with results from the BeSt study, however, for a univariate analysis (for high 
37 
 
MBDA score compared with low/moderate at baseline, RR=3.7) (293). Few more studies, 
including the BeSt study illustrated predictive ability of the MBDA score for RP (292-295), 
even though two of these studies (293, 294) used slightly different cut-offs for RP (ΔSHS>0 
or >3). 
 
 
4.1.3 Association of the MBDA score at follow-ups with subsequent RP 
In the paper II, we demonstrated that the MBDA score at follow-ups was also informative for 
RP during subsequent year (Figure 6). None of the patients achieving low MBDA score from 
moderate (n=11) and only one patient of those who dropped from high category to low (n=17) 
during 3 months of MTX monotherapy, had RP at 1 year. In contrast, patients who were 
persistently high at 3 months (n=88), 25% had RP. Similar associations were observed when 
looking at conversion of the MBDA category from baseline to 1 year and RP during the 
second year of the follow-up (Figure 6B). CRP and ESR in contrast, could not perform the 
identification or risk for RP similarly well. 
Table 5. Univariate bivariate and multivariate analyses of baseline MBDA score, DAS28 and CRP as predictors of one year radiographic progression.
Odds Ratio† 95% CI P-Value‡
Univariate Analyses:
Baseline MBDA score 1.05 (1.02, 1.08) <0.001
Baseline DAS28-ESR 1.31 (0.94, 1.81) 0.107
Baseline DAS28-CRP 1.22 (0.88, 1.71) 0.237
Baseline CRP (mg/L) 1.10 (1.02, 1.18) 0.018
Bivariate Models:
Baseline MBDA adjusted for DAS28-ESR 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for DAS28-CRP 1.05 (1.02, 1.09) <0.001
Baseline MBDA adjusted for CRP 1.06 (1.02, 1.10) 0.002
Baseline MBDA adjusted for ESR 1.04 (1.01, 1.07) 0.021
Baseline MBDA adjusted for Rheumatoid Factor 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for CCP Status 1.05 (1.03, 1.08) <0.001
Baseline MBDA adjusted for Total Swollen Joint Count 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for Total Tender Joint Count 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for Global Assessment of Disease Activity 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for SHS 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for Symptom Duration 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for Sex 1.05 (1.02, 1.08) <0.001
Multivariate Model*:
Baseline MBDA adjusted for Sex, Symptom Duration, baseline erosions, current smoking status, HAQ score 1.05 (1.02, 1.08) <0.001
High (>44) baseline MBDA score adjusted for Sex, Symptom Duration, baseline erosions, current smoking status, HAQ score 3.86 (1.04, 14.26) 0.04
† The odds ratio was estimated from a logistic regression model.  The logistic model is estimating the probability of radiogr aphic progression at year 1.
For the univariate model, the odds of radiographic progression increases by 5% for every one -unit increase in the baseline MBDA score. When accounting for other disease activity 
measures individually (bivariate models), the odds of radiographic progression increase in a cumulative manner, approximately 4-6% for every one-unit increase in the baseline MBDA 
score.
‡  P-value was calculated using Wald’s chi-square test.
*Multivariate model adjusted for significant univariate predictors of one year radiographic progression (n=207), as in Saevarsdottir S et al, Current smoking status is a strong predictor 
of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial, ARD in press.
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Baseline MBDA adjusted for ESR 1.04 (1.01, 1.07) 0.021
Baseline MBDA adjusted for Rheumatoid Factor 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for CCP Status 1.05 (1.03, 1.08) <0.001
Baseline MBDA adjusted for Total Swollen Joint Count 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for Total Tender Joint Count 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for Global Assessment of Disease Activity 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for SHS 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for Symptom Duration 1.05 (1.02, 1.08) <0.001
Baseline MBDA adjusted for Sex 1.05 (1.02, 1.08) <0.001
Multivariate Model*:
Baseline MBDA adjusted for Sex, Symptom Duration, baseline erosions, current smoking status, HAQ score 1.05 (1.02, 1.08) <0.001
High (>44) baseline MBDA score adjusted for Sex, Symptom Duration, baseline erosions, current smoking status, HAQ score 3.86 (1.04, 14.26) 0.04
† The odds ratio was estimated from a logistic regression model.  The logistic model is estimating the probability of radiogr aphic progression at year 1.
For the univariate model, the odds of radiographic progression increases by 5% for every one -unit increase in the baseline MBDA score. When accounting for other disease activity 
measures individually (bivariate models), the odds of radiographic progression increase in a cumulative manner, approximately 4-6% for every one-unit increase in the baseline MBDA 
score.
‡  P-value was calculated using Wald’s chi-square test.
*Multivariate model adjusted for significant univariate predictors of one year radiographic progression (n=207), as in Saevarsdottir S et al, Current smoking status is a strong predictor 
of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial, ARD in press.
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Figure 6. Association of radiographic progression with change in disease activity categories 
according to the MBDA score, CRP and ESR. Change in categories according to MBDA score, CRP or 
ESR from BL to Month 3 and radiographic progression from BL to Year 1 (A); and change in categories 
according to MBDA score, CRP or ESR from BL to Year 1 and radiographic progression from Year 1 to 
Year 2 (B). 
 
In the second paper, we also observed differential association of the MBDA score at baseline 
or 3 months with RP at 2 years, for each of the randomised treatment arm. Among patients 
with high MBDA score, those on TT had significantly higher proportion of RP compared with 
patients on biological therapy (Figure 7A: 45% vs 25% and 57% vs 32%, respectively; p<0.05 
for both comparisons). 
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Figure 7. Radiographic progression among 3 therapy groups (triple therapy group, anti-TNF 
treatment group and MTX-responders) stratified by MBDA categories at multiple time-points. 
Proportion of patients with radiographic progression defined as ∆SHS>5 (A) and ∆SHS>3 (B). Left and 
middle bar-graphs represent proportion of patients with 2-year radiographic progression stratified by 
the MBDA score at BL and Month 3, respectively. Right bar-graph shows radiographic progression 
from Year 1 to Year 2 among patients stratified by the MBDA score at Year 1. 
 
4.2 STUDY II (PAPER III) 
4.2.1 Association of validated categories of the MBDA score with treatment outcome 
It has been shown previously that of patients randomised to MTX+IFX therapy, significantly 
more proportion achieved EULAR good response than from patients on TT (39% vs 25%, 
respectively; p=0.016) (96). Even being statistically significant, the difference is not very 
large from clinical point of view. In MTX-incomplete responders, the MBDA score categories 
at the time of treatment randomisation yielded clinically meaningful difference and moreover, 
it identified a subgroup that had a higher chance of achievement of LDA on TT compared 
with patients on IFX (Figure 8). Namely, of patients with low MBDA score, more patients 
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achieved LDA if treated with TT than with IFX (88% vs 18%, p=0.006) and reverse was true 
for patients with high MBDA score (35% vs 58%, p=0.040). 
 
Figure 8. Proportion of patients with response (DAS28≤3.2) to second-line therapy at Year 1 
stratified by conventional cut-offs of MBDA score at the start of treatment intensification. 
Proportion of responders at Year 1 to triple therapy (grey bars) or anti-TNF therapy (white bars) 
stratified by low (<30), moderate (30-44), and high (>44) MBDA categories at Month 3. 
 
4.2.2 New threshold of the MBDA score for prediction of treatment outcome 
ROC curve analysis yielded a cut-off of 38 for dichotomisation of patients into higher and 
lower categories, which illustrated similar associations (79% vs 44%, respectively, p=0.019 
and 36% vs 58%, respectively, p=0.018; Figure 9). Other inflammatory markers (CRP, ESR 
and DAS28) at 3 months did not illustrate or showed a weaker association. 
Our findings support the results from the RACAT trial demonstrating that of patients not 
responding to MTX+etanercept, some switchers to TT responded, while some of non-
responders on TT who switched to MTX+etanercept also achieved better clinical outcome 
(94). The MBDA score compared with DAS28, ESR and CRP is a multi-component 
molecular marker which probably indicates changes much earlier than the clinical or mono-
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component molecular markers can do. Thus, validation of these results could lead to reduction 
of unnecessary use of biological drugs for a subgroup of patients, while indicator for their 
successful use for another subset of patients. 
 
Figure 9. Proportion of clinical responders (DAS28≤3.2) to second-line therapy at Year 1 stratified 
by ROC-based cut-offs of disease activity measures at Month 3. Proportion of responders at Year 1 
to triple therapy (grey bars) or anti-TNF therapy (white bars) stratified by MBDA score (A), CRP (B), 
ESR (C) and DAS28 (D). The overall p-values for 4 groups are calculated by Breslow-Day test, and for 
triple therapy versus anti-TNF therapy groups – by χ2 test, unless otherwise stated. 
†p-value was calculated using Fisher’s Exact test. 
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4.3 STUDY III (PAPER IV AND V) 
In early RA patients treated with MTX, baseline serum levels of biomarkers were analysed for 
associations with achievement of treatment outcome (LDA or EULAR good response) at 3 
months follow-up. 
 
4.3.1 Study IIIa (paper IV) 
In the paper IV, the 12 component proteins of the MBDA score were analysed as potential 
predictors of response to MTX. 
 
4.3.1.1 Identification of potential predictors  
Of 298 analysed patients 104 achieved LDA. Among baseline parameters, as it has been 
previously published (98), sex, age and some clinical parameters were significantly different 
between patients achieving and not achieving LDA at 3 months (Table 6).  
 
Table 6. Baseline characteristics of early RA patients from the SWEFOT trial 
Baseline Characteristics 
Median (±IQR) 
Stratified by disease activity (DAS28) at 3 months follow-up 
DAS28 ≤ 3.2 (N=104)
a
 DAS28 > 3.2 (N=194)
b
 P-value 
Female: N (%) 60 (58) 154 (79) <0.001 
Age: years 61 (51-69) 55 (44-62) 0.001 
Smoking: N (%) 19 (24) 47 (26) 0.780 
Symptom Duration: months 5 (3-8) 5 (4-8) 0.283 
Anti-CCP Positive: N (%) 63 (64) 107 (58) 0.292 
RF Positive: N (%) 73 (71) 124 (65) 0.274 
Prednisolone use: N (%) 15 (14) 20 (10) 0.293 
28 Swollen Joint Count 9 (7-13) 11 (7-15) 0.087 
28 Tender Joint Count 6 (4-10) 10 (6-15) <0.001 
ESR (mm/h) 28 (15-42) 36 (24-62) 0.001 
CRP (mg/L) 15 (9-33) 20 (9-53) 0.033 
PatG (VAS 0-100mm) 50 (29-67) 63 (43-77) 0.001 
Pain (VAS 0-100mm) 49 (33-64) 62 (46-74) <0.001 
HAQ 1.0 (0.50-1.38) 1.25 (0.88-1.75) <0.001 
DAS28 5.2 (4.6-5.9) 5.9 (5.3-6.4) <0.001 
IQR – interquartile range, anti-CCP - anti-cyclic citrullinated peptide, RF – rheumatoid factor, ESR – erythrocyte sedimentation rate, CRP – C-
reactive protein, PatG – Patient’s Global Assessment of Disease Activity score, VAS – visual analogue scale, HAQ, - health assessment 
questionnaire, DAS – disease activity score. a
 Missing patients from DAS28≤3.2 column: Smoking (n=25), Anti-CCP (n=6) and RF (n=1). b Missing patients from DAS28>3.2 column: Smoking (n=11), Anti-CCP (n=9), RF, PatG and Pain (n=2), HAQ (n=4) and DAS28 (n=3).  
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The MBDA score did not differ between these 2 groups of patients. In CAMERA trial, on the 
other hand, the MBDA score was associated with DAS28-CRP and discriminated patients 
between remission/low and moderate/high disease activity levels (287). In a univariate 
analysis, four of the 12 proteins differed at a level of p<0.05 (Table 7). 
 
Table 7. Baseline biomarkers of early RA patients from the SWEFOT trial 
Baseline Biomarkers 
Median (±IQR) 
Stratified by disease activity (DAS28) at 3 months follow-up 
DAS28 ≤ 3.2 (N=104)
a
 DAS28 > 3.2 (N=194)
b
 P-value 
VCAM-1 (mg/L) 0.70 (0.60-0.86) 0.64 (0.56-0.77) 0.005 
TNF-RI (μg/L) 1.9 (1.6-2.4) 1.7 (1.4-2.2) 0.005 
IL-6 (ng/L) 49 (22-97) 67 (29-150) 0.044 
CRP (mg/L) 20 (8-43) 27 (10-110) 0.045 
MMP-1 (μg/L) 9.35 (5.87-15) 11 (6.48-18) 0.067 
MMP-3 (μg/L) 48 (28-82) 56 (29-123) 0.105 
Leptin (μg/L) 9.25 (3.58-14) 10.50 (4.60-20.25) 0.108 
VEFG (ng/L) 405 (265-600) 390 (250-590) 0.719 
Resistin (μg/L) 6.60 (5.35-8.78) 6.80 (5.10-8.68) 0.857 
YLK-40 (μg/L) 85 (54-120) 79 (57-130) 0.862 
EGF (ng/L) 160 (103-258) 170 (100-253) 0.903 
SAA (mg/L) 20 (7-46) 17 (4-73) 0.990 
MBDA score 59 (47-66) 59 (49-74) 0.143 
IQR – interquartile range, DAS – disease activity score, VCAM-1 - vascular cell adhesion molecule-1, TNF-RI - tumour nectosis factor receptor-1, 
IL-6 - interleukin-6, CRP – C-reactive protein, MMP - matrix metalloproteinase, VEGF - vascular endothelial growth factor, YKL-40 - human 
cartilage glycoprotein-39, EGF - epidermal growth factor, SAA - serum amyloid A, MBDA – multi-biomarker disease activity. 
 
Biomarkers that had p-value <0.2 (n=7), were entered into a multivariate logistic regression 
model for identification of LDA at 3 months as a dependent outcome. Four of these 
biomarkers were independently associated with LDA (increase in concentrations of VCAM-1 
and TNF-RI, as well as decrease in CRP and leptin were associated with LDA, Table 8). 
There is no clear data regarding these four biomarkers illustrating predictive capacity for 
response to MTX. Controversial results are published by different researchers regarding CRP, 
some illustrating association of its low level with response (110) and some failing to do so 
(114, 318-320). The association of high baseline leptin levels with high DAS28 at 6 months in 
RA patients treated with non-biological DMARDs was illustrated by a research group (262). 
Being associated with BMI, we could not find any relation of BMI with treatment outcome in 
our study (data not shown). Increased sTNF-RI might indicate increased sTNF, since cleavage 
of membrane-bond TNF-RI is considered as negative regulation of increased production of 
TNF and inflammation (decoy receptor) (200, 201). Considering this fact and since MTX is 
known to decrease TNF level (321, 322), higher levels of TNF-RI could mean a disease 
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driven by TNF, where MTX could be a proper option for treatment. Indeed, a study has 
demonstrated that patients with high sTNF-RI had better response to MTX (161). 
 
Table 8. Multivariate logistic regression of protein biomarkers at 
baseline for prediction of low DAS28 at 3 months 
Biomarkers OR 95% CI 
VCAM-1 (per mg/L increase) 6.70 1.17-38.62 
TNF-RI (per μg/L increase) 3.10 1.70-5.71 
IL-6 (per ng/L increase) 0.99 0.99-1.00 
CRP (per mg/L increase) 0.99 0.98-0.99 
MMP-1 (per μg/L increase) 0.98 0.94-1.01 
MMP-3 (per μg/L increase) 1.00 0.99-1.00 
Leptin (per μg/L increase) 0.97 0.95-0.99 
Results after step-wise logistic regression analysis 
VCAM-1 (per mg/L increase) 8.19 1.47-45.65 
TNF-RI (per μg/L increase) 2.48 1.43-4.31 
CRP (per mg/L increase) 0.99 0.98-0.99 
Leptin (per μg/L increase) 0.97 0.95-0.99 
VCAM - vascular cell adhesion molecule, TNF-RI - tumour necrosis factor receptor 1, IL-6 
- interleukin-6, CRP - C-reactive protein, MMP - matrix metalloproteinase, OR - odds 
ratio, CI - confidence interval 
 
 
4.3.1.2 Dichotomisation of biomarker levels 
ROC curve analyses identified cut-off levels based on highest sum of sensitivity and 
specificity generating low and high categories for these biomarkers: CRP: ≤51.5 and >51.5 
mg/ml, leptin: ≤14.5 and >14.5 μg/ml, TNF-RI: ≤1.75 and >1.75 μg/ml and VCAM-1: ≤0.605 
and >0.605 mg/ml. There were significantly higher proportions of patients achieving LDA 
among subjects with low CRP and leptin, and high TNF-RI and VCAM-1 (Figure 10). 
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Figure 10. Proportions of eRA patients achieving low disease activity after 3 months of MTX 
monotherapy, stratified for different biomarkers. Proportions of patients with low DAS28 in 
patients dichotomised according to CRP (A), leptin (B), TNF-RI (C) and VCAM-1 (D). DAS28 – disease 
activity score based on 28 joints, CRP – C-reactive protein, DAS28 – 28-joint disease activity score, 
MTX – methotrexate, TNF-RI – tumour necrosis factor receptor-1, VCAM-1 – vascular cell adhesion 
molecule-1. 
 
4.3.1.3 Combined biomarker score 
The combined biomarker score that was based on the four proteins, was independently 
associated with treatment outcome (odds ratio adjusted for RF, ACPA, sex, age and current 
smoking OR=0.44, 95CI=0.30-0.65). There was a gradual decrease in proportion of patients 
in LDA or EULAR good response with increase of the combined biomarker score (Figure 11). 
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Figure 11. Proportions of early RA patients achieving low DAS28 or EULAR good response after 3 
months of MTX monotherapy, stratified for the combined biomarker score. Proportions of patients 
with low DAS28 (A) or EULAR good response (B) within subsets based on the combined biomarker 
score: combined score = 0 (green bars), combined score = 1 (blue bars), combined score = 2 (orange 
bars), combined scores = 3 (red bars) and combined score = 4 (black bars). 
 
The biomarker score was tested in combination with previously published (98) predictors (sex 
and age) for identification of patients achieving treatment outcome. Even though one of the 
components of the combined biomarker score has a co-linearity with sex (females have higher 
leptin level compared with males), the combined prediction matrix identified subset of 
patients with very high predictability of response. For example, among older male patients 
with the lowest combined biomarker score (n=14), 13 achieved LDA and 12 EULAR good 
response, while among younger female patients with the combined biomarker score of 3 and 4 
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Figure 11. Proportions of early RA patients achieving low DAS28 or EULAR good response after 3 
months of MTX monotherapy, stratified for the combined biomarker score. Proportions of patients 
with low DAS28 (A) or EULAR good response (B) within subsets based on the combined biomarker 
score: combined score = 0 (green bars), combined score = 1 (blue bars), combined score = 2 (orange 
bars), combined scores = 3 (red bars) and combined score = 4 (black bars). 
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Figure 12. Matrix of prediction of response to MTX in early RA patients, based on age, gender and 
combined biomarker score. Proportion of patients achieving low DAS28 (A) or EULAR good response 
(B). 
The main limitation of the study is the limited number of patients in some subgroups which 
emphasises the need for validation in other study populations. The SWEFOT trial, on the 
other hand, is designed with low bias, due to the few exclusion criteria and routine-care based 
recruitment, and all patients were treated with MTX, which is the recomendet first-line 
therapy today. 
4.3.2 Study IIIb (paper V) 
4.3.2.1 Identification of predictive proteins 
The 135 patients included in this study had more often RF than the remaining patients from 
the SWEFOT population (72% and 58%, respectively, p=0.002). Of screened 177 serum 
proteins at baseline, in univariate analysis, eight had different level of MFI (at the level of 
p<0.001) among patients achieving and not achieving LDA at 3 months. Of the eight 
candidate biomarkers, two: MMP-7 and α-chain of fibrinogen (FGA) were independently 
associated with treatment outcome. The ROC curve analysis resulted in area under the curve 
of 0.692 and 0.699 for MMP-7 and FGA, respectively (p<0.001, Figure 13A). Low levels of 
the two biomarkers indicated significantly higher proportion of patients in LDA at 3 months 
(Figure 13B). 
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Figure 13. Assessment of baseline levels of MMP-7 and FGA as predictors of LDA at 3 months. 
Receiver operating characteristic curve analysis and area under the curve (A) of MMP-7 (green line), 
FGA (red line); Proportion of patients achieving low DAS28 at 3 months among groups dichotomised 
by MMP-7 or FGA (B) low levels – purple bars and high levels – yellow bars. 
 
When considering both biomarkers simultaneously, of patients with low levels for both 
biomarkers, 79% had LDA and EULAR good response, while of those with high levels for 
both biomarkers, 18% and 15%, respectively achieved LDA or EULAR good response 
(p<0.001, Figure 14). 
 
Figure 14. Assessment of combined baseline levels of MMP-7 and FGA as predictors of outcome. 
Proportion of patients in LDA (A) and EULAR good response (B) among patients with low/low (purple 
bar), high/high (yellow bar), low/high (green bar) and high/low (blue bar) categories of MMP-7/FGA. 
 
4.3.2.2 An attempt of replication of the results for MMP-7 in the COMBINE cohort 
Neither MMP-7 nor FGA have been shown to predict response to MTX. Validation of results 
for MMP-7 in another RA cohort (COMBINE, N=74) did not confirm the finding. We found 
three differences between the SWEFOT and COMBINE cohorts: method of measuring MMP-
7, significantly lower glucocorticoid use and significantly higher DAS28 at baseline and at 3 
months among patients from SWEFOT compared with COMBINE cohort. When considering 
only patients treated without glucocorticoids, we still could not confirm the association of 
baseline low MMP-7 with LDA at 3 months in COMBINE cohort. Therefore, we assume that 
method of measurement of MMP-7 and baseline DAS28 could contribute to the bias. 
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Confirmation of these results in another similar RA cohort with untreated early RA patients 
using the same method of measurement, might increase efficiency of MTX monotherapy 
choice in treatment of RA. 
 
4.4 STUDY IV (PAPER VI) 
4.4.1 Distribution of data 
Immunogenicity of biological medications has been established as a challenge for 
achievement of optimal treatment outcome (310, 323). Of 289 available serum samples (from 
all 3 time-points together), we observed a very low sIFX level (<0.2 μg/ml) in 64 samples, 
and of those, 47 (73.4%) were ADA-positive. Of 101 patients analysed in this study, 34 
patients were ever ADA-positive. There were no baseline parameters significantly different 
between ever and never ADA-positive patients. However, there were more women among 
ever (85%) compared with never (67%) ADA-positive patients, respectively (p=0.052, Table 
9) with similar trend for RF-positivity (79% vs 62%, p=0.0079). 
Table 9. Characteristics of SWEFOT participants at the time of randomization to 
IFX stratified into ever and never anti-drug antibody positive patients 
Patient Characteris, MTX-incomplete responders randomized to IFX therapy (N=101) 
  
Median (IQR)
a
 All (N=101)b 
Ever ADA-positive 
(N=34)
c
 
Never ADA-
positive (N=67)
d
 
P-value
e
 
Female: N (%) 74 (73) 29 (85) 45 (67) 0.052 
Age (years) 55 (43-62) 50 (42-59) 55 (44-63) 0.246 
BMI 24.2 (22.2-26.4) 23.8 (22.2-27.0) 24.4 (22.3-26.2) 0.740 
Current Smokers: N (%) 27 (27) 10 (29) 17 (25) 0.665 
Symptom Duration (months) 6 (4-8) 6 (3-9) 5 (4-8) 0.610 
Anti-CCP Positive: N (%) 62 (67) 22 (71) 40 (64) 0.534 
RF Positive: N (%) 68 (68) 27 (79) 41 (62) 0.079 
28 Swollen Joint Count 6 (3-10) 4 (3-9) 6(3-10) 0.483 
28 Tender Joint Count 6 (4-10) 7 (4-12) 6 (3-9) 0.134 
ESR (mm/h) 23 (12-37) 24 (14-37) 21 (11-34) 0.446 
CRP Level (mg/L) 9 (4-17) 9 (4-15) 9 (4-18) 0.853 
PatG (VAS 0-100mm) Score 49 (35-67) 50 (36-67) 49 (34-68) 0.979 
Pain VAS 47 (30-64) 44 (30-66) 49 (30-63) 0.740 
PhysG 2 (2-2) 2 (2-2) 2 (2-2) 0.392 
HAQ 0.9 (0.63-1.38) 0.9 (0.38-1.25) 1.0 (0.63-1.38) 0.081 
DAS28 4.9 (4.1-5.6) 5.0 (4.3-5.8) 4.8 (4.1-5.5) 0.328 
ADA – anti-drug antibody, IQR – interquartile range, IFX – infliximan, BMI – body mass index, anti-CCP - anti-cyclic citrullinated 
peptide, RF – rheumatoid factor, ESR – erythrocyte sedimentation rate, CRP – C-reactive protein, PatG – Patient’s Global 
Assessment of Disease Activity, VAS – visual analogue scale, PhysG – Physician Global Assessment of Disease Activity, HAQ – 
health assessment questionnaire, DAS – disease activity score. 
a Data for Female, Age, Current Smoking, Symptom Duration, Anti-CCP and RF are presented from diagnosis and trial recruitment 
date. 
b Number of missing patients for “101” column: BMI (n=27), Anti-CCP (n=8), RF (n=1), 28 Swollen Joint Count, 28 Tender Joint 
Count, CRP, PatG VAS (n=3), ESR, Pain VAS, PhysG and HAQ (n=4). 
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c Number of missing patients for IFX-Responders column: BMI (n=7), Anti-CCP (n=3), 28 Swollen Joint Count, 28 Tender Joint 
Count, ESR, CRP, PatG VAS, Pain VAS, PhysG and HAQ (n=1). 
d Number of missing patients for IFX-non-responders column: BMI (n=20), RF (n=1), Anti-CCP (n=5), 28 Tender Joint Count, 28 
Swollen Joint Count, CRP and PatG VAS (n=2), ESR, Pain VAS, PhysG and HAQ (n=3). 
e Comparing ever and never ADA-positive patients. 
 
4.4.2 Association of sIFX levels and ADA status with treatment outcome 
Higher proportion of patients in LDA or remission was observed among patients with sIFX 
>0.2 μg/ml compared with ADA-positive patients, and the difference was significant at the 
study cessation (at 21 months, Figure 15A and B). Similarly higher sIFX level was associated 
with better clinical outcome (Figure 15C and D). These results are in concordance with 
previous studies (303, 305, 310, 324). 
 
Figure 15. Clinical outcome of patients at 3, 9 and 21 months stratified for sIFX and ADA status. 
Proportion of patients in LDA (A) and remission (B) among patients with sIFX level ≥0.2 μg/ml (blue 
dots) and ADA-positive patients with very low sIFX levels (red dots). Proportion of patients in LDA (C) 
and remission (D) among four strata of patients according to sIFX levels: very low sIFX level – blue 
bars, 0.2-2.9 μg/ml – red bars, 3.0-7.0 μg/ml – green bars, and >7.0 μg/ml – orange bars. 
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4.4.3 Prediction of low sIFX or ADA 
Gender and RF status among other baseline parameters showed borderline significnat 
associations with ever ADA-positivity. In multivariate analyses, female gender and RF-
positivity remained borderline significantly associated with development of ADA. Higher 
frequency of ADA-positivity among women compared with men could be explained by the 
fact that B cells in females have higher capacity for antibody production (325). However, 
there are controversial data regarding associations of RF and gender with ADA status (324, 
326). Unlike SWEFOT, patients from these studies have significantly higher disease duration 
(6-14 years) and lower incidence of ADA-positive patients, which indicates more suppressed 
immune system by long-lasting DMARD therapy, leading to reduced capacity of antibody 
production. In addition, RF may interfere with ELISA kit for ADA measurement and give 
false-positive results. However, we also observed a trend of RF-positivity with low sIFX 
level, and the trend became stronger at 21 months (34% vs 16%, p=0.059, Figure 16). Similar 
trend was observed when comparing female versus male patients with significant difference at 
21 months (35% vs 7%, respectively, p=0.006, Figure 16). 
 
 
Figure 16. Proportion of patients with very low sIFX level at 3, 9 and 21 months stratified for RF 
and gender. Blue bars represent proportion among RF-negative and red bars – among RF-positive 
subset. Green bars represent proportion among males and orange bars –among females. 
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It is important to note that sIFX levels analysed in this study were from samples taken at 
follow-up visits and not just before next infusion (i.e. trough levels), which is the biggest 
limitation. However, confirmation of associations of the sIFX levels and ADA-positivity with 
treatment outcome at later time-point, found by others researchers at earlier time-points 
indicates that the trend associations observed in our study could be strengthened if trough 
levels are used. Therefore, further investigations of prediction of response to IFX using sIFX 
levels, ADA and other baseline parameters might help identify patients at higher risk and 
improve decision-making for the switch of biological therapy. 
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5 CONCLUSION 
 
In the presence of different treatment options for RA and the heterogeneity of the disease, 
there is a huge need for predictive tools to help chose the optimal treatment for each 
individual patient. This thesis project overall, tried to address this question via exploratory 
analyses of serum proteins, as potential predictors of treatment outcome. 
In paper I and II we showed predictive capacity of the MBDA score at baseline and follow-
ups for RP during subsequent one or two years. Apart from confirming the association of low 
MBDA score with very low risk of RP and superiority of the MBDA score compared to CRP, 
ESR and DAS28, we also showed for the first time that patients with high MBDA score 
would benefit more from MTX+IFX therapy than from TT to lower RP. 
In paper III, the MBDA score identified a subset of patients that benefited significantly more 
from TT compared with biological IFX treatment, a finding that yielded much attention since 
TT is much cheaper, and has now been supported by results from O’Dell et al (94). 
Paper IV and V highlighted some protein biomarkers at baseline for prediction of response to 
MTX monotherapy. As in all biomarker studies, those findings need to be validated since 
these molecules can be potential key players in the pathology of some RA patients. 
In paper VI we confirmed previously published results on association of low sIFX levels and 
ADA-positivity with poorer treatment response to IFX, but also found that RF and female 
gender might be risk factors for immunogenicity and low sIFX levels. 
In summary, through investigations of serum proteins related to inflammation we identified 
potential predictors of RP and clinical outcome, which may help to understand pathology 
behind RA and aid therapy choice. For biological treatment, studies of immunogenicity and 
blood trough level of the drug support routine monitoring of sIFX and ADA in the clinic and 
serve as basis for development of an algorithm when to switch to other treatment options. 
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